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ABSTRACT
The world-wide demand for recombinant proteins continuously increases as new medical
and industrial applications are developed. Higher plants have the potential to help meet this
rising demand as green bioreactors. A major hurdle, however, is low recombinant protein yields
in higher plants and, as with many production systems, high cost associated with downstream
purification and the production of short peptides. The goal of this research was to address each
of these problems to further increase the utility of plant bioreactors.
The short antigenic peptide 277 (p277) from heat shock protein 60, which has the
potential for use in the prevention of type 1 diabetes, was fused to an known adjuvant, the nontoxic B subunit of cholera toxin (CTB). The fused CTB-p277 retained the ability to form a
homo-tetramer, and bound to GM1 ganglioside, allowing for the oral delivery of the fusion
protein to induce mucosal tolerance and prevention of diabetes.
Protein yield increases can be achieved by either increasing overall plant yield or
increasing the relative accumulation of the desired protein. Using RNA interference, a
knockdown of Solanum tuberosum plastidic ATP/ADP transporter, involved in energy transport
into heterotrophic plastids, resulted in a 30% increase in tuber biomass, as well as a two-fold
increase in soluble protein content. In addition, expression of a monoclonal antibody in the
knockdown line produced double the concentration of antibody per soluble protein compared to
wild-type. Taken together, this is a 4-fold yield increase compared to wild-type.
Protein purification accounts for a significant portion of its production cost. We
developed the recombinant production of soybean agglutinin (SBA) for potential use as an
iii

affinity tag. SBA was purified to high quality using an agarose-N-acetyl-D-galactosamine
column, resulting in a 1-step purification process. Recombinant SBA performed identically to
native SBA during in vitro assays, including agglutination of red blood cells (RBC). A fusion of
SBA with green fluorescent protein (GFP) resulted in SBA-GFP that retained its in vivo
fluorescence, purification through a 1-step process as well as the ability to agglutinate RBC and
in vitro fluorescence of the agglutinated cells.

Keywords: ATP/ADP transporter, soybean agglutinin, p277, heat shock protein 60, green
bioreactor, cholera toxin b subunit, recombinant protein production, higher plants, tobacco,
potato
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CHAPTER 1

GENERAL INTRODUCTION

2

1.1 Plants as green bioreactors
There is ever increasing demands for recombinant proteins for use in biomedical
research, industrial production and for academic investigation. Traditional recombinant
production systems, such as both prokaryotic and eukaryotic cell culture, have limitations due in
large part to scalability, drastically increasing the cost of production as demands rise. In addition,
there are a number of host platform-specific limitations, including pathogen contamination
(mammalian cell culture) and lack of post-translation modification (prokaryotic reactors). Plants
may offer the solution as green bioreactors, offering a variety of advantages such as nearly
unlimited scalability, from small scale trials in growth chambers to large open-field mass
production, and all at relatively inexpensive cost. Additionally, as eukaryotes, plants are capable
of a suite of post-translational modifications such as glycosylation and disulphide bridging, and
have enhanced biosafety over production in mammalian cell culture systems, as there are no
known cross-kingdom pathogens (Tremblay et al. 2010b). For biomedical therapeutics, plants
also offer the potential for oral delivery of minimally processed tissue, drastically reducing the
cost of treatments (Arakawa et al. 1998; Ma et al. 1997; Ploix et al. 1999). The range of products
produced in plants to date is extensive, with everything from monoclonal antibodies to treat
human diseases to cellulose digesting enzymes for biofuel production (McCormick et al. 1999;
Hood et al. 2007; Floss et al. 2008; Strasser et al. 2008; Zhou et al. 2008; Rosales-Mendoza et al.
2011).
1.2 Plant bioreactors
1.2.1 Seed and fruiting body systems
A wide variety of plant reproductive structures have been used to generate and store
recombinant proteins, including seeds in cereals and legumes, as well as fruits such as tomato
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(Ma et al. 2003; Ramirez et al. 2007; Ludwig et al. 2004; Rosales-Mendoza et al. 2011; Cunha et
al. 2010). Seeds are attractive bioreactors for a variety of reasons, including the potential for high
accumulation in protein storage bodies and simplified long-term storage (Stoger et al. 2000). For
therapeutic proteins, many seed and fruiting body expression platforms can be used directly for
oral delivery with minimal processing, such as immunization against the Norwalk virus through
oral delivery of tomato expressing the Norwalk capsid protein (Zhang et al. 2006).
Despite the above advantages, the use of plant reproductive tissue presents a major
problem, namely the increased risk of environmental contamination. The production of pollen
provides an opportunity for contamination of plants earmarked for human consumption, as well
as the potential for outcrossing to wild relatives. This risk can be partially overcome through the
use of male-sterile lines for the expression of recombinant proteins, preventing the spread of
pollen containing the recombinant protein or its coding sequence (Feil et al. 2003). In fruit-based
expression, the level of recombinant protein is typically low and non-uniform, creating
difficulties in accurately producing doses for ingestion, although it is possible to reach
uniformity through batch production and homogenization (Joensuu et al. 2008).
1.2.2 Potato
Potato (Solanum tuberosum) tubers have been used to accumulate a wide variety of
recombinant proteins, including monoclonal antibodies, viral coat proteins, cytokines, plant
lectins and insulin (Mason et al. 1996; Arakawa et al. 1998; De Wilde et al. 2002; Tremblay et
al. 2010a; Richter et al. 2000; Carrillo et al. 2001; Yu and Langridge 2003; Ma et al. 2005).
Potato offers a number of advantages as a bioreactor over other plants species. First and foremost
is biomass accumulation, with nearly 30 tonnes per hectare of tubers commonly harvested,
compared to 2 to 3 tonnes per hectare for grain species (Statistics Canada, 2010). While tuber
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protein content is relatively low, the amount of biomass accumulation more than offsets this
deficiency, with only soybean producing more protein per hectare on average. Secondly,
recombinant proteins produced in tubers are stable. For example, following six months of cold
storage, tubers had lost less than 10% of a recombinant monoclonal antibody (De Wilde et al.
2002). One proposed reason for this is tubers produce a significant quantity of proteinase
inhibitors and are thought to stabilize native tuber proteins during extended dormancy (Weeda et
al. 2009). Potato transformation is relatively simple, achieved by incubating Agrobacterium with
either leaf or tuber discs (Bourque et al. 1987). In addition to these advantages, potato propagates
vegetatively, drastically reducing the risk of environmental outcrossing, although do to the
harvested biomass occurring below the surface, residual plants may overwinter in the field.
Potato tubers develop from the terminal ends of underground stems called stolons (See
Figure 1.1). The forming tuber begins to enlarge along the transverse axis of the stolon, with an
increase in the accumulation of protease inhibitors, as well as storage proteins, particularly
patatin (Weeda et al. 2009). Large-scale starch accumulation occurs during the bulking phase,
when sugars imported from the leaves into tuber parenchyma with starch-containing plastids
called amyloplasts. The imported sugars are linked through 1,4-glycosidic bonds to form
amylose, which are linear chains of starch, and can be subsequently branched through 1,6glycosidic bonding, creating amylopectin.
As mentioned above, low protein concentration is a drawback to potato. While overall
yield is high, the requirement to process 10 times the tissue to achieve comparable levels of

5

Figure 1.1: Diagram of a potato plant. a) Depiction of the aerial and below ground portion of a potato plant. Tubers
develop at terminal ends of stolons, which are below ground stems that can give rise to aerial portions. b) Depiction
of a potato tuber. Leaf scars subtend eyes, which are meristematic tissue that give rise to stolons following periods
of dormancy to generate new plants.

6

protein yield of grains per hectare increases the post-production costs. As with all plant
bioreactors that are based in food staples, there is also a risk of contamination of the food chain.
1.2.3 Nicotiana species
Two species of Nicotiana, tabacum (tobacco) and benthamiana (a close relative of
tobacco), are routinely used for the production of recombinant proteins. Tobacco offers several
advantages as a green bioreactor. First and foremost, tobacco is not part of the food supply chain,
removing the risks for accidental contamination. Secondly, tobacco leaf-based bioreactors
eliminate the requirement for pollination, and existing agricultural infrastructure is designed with
leaf harvest in mind. In addition, it would offer current tobacco farmers an alternative crop
destination point, from cancer-causing to therapeutic-producing tobacco. The equipment used for
tobacco harvesting is specific to tobacco and so for farmers to switch to a different crop would
require massive changes in infrastructure. Tobacco also has a high yield, with upwards of 100
tonnes per hectare of leafy green material per year. Known as the “white mouse” of the plant
world, tobacco is also one of most heavily studied recombinant protein expression systems, with
a variety of expression options readily available, including transient and stable expression
(Tremblay et al. 2010b). Oral delivery is also a possibility, as low-nicotine low-alkaloid
varieties, such as 81V9, have proven safe in animal feeding trials (Menassa et al., 2007)
1.3 Medically valuable protein production in green bioreactors
1.3.1 Antibodies
Recombinant antibodies are useful for a variety of therapeutic interventions and make up
the bulk of protein therapeutics under development. Monoclonal antibody production requires
the coordinated assembly of a heavy and light chain. The first plant-made antibody, an anti-
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mouse IgG1, was produced by expressing the heavy and light chains in two different plants and
then crossing the two independent lines together (Hiatt et al. 1989). Since that time, a wide range
of antibodies have been produced in plant bioreactors. The first plant-made antibody approved
for human use, CaroRxTm, is a secretory IgA antibody that prevents the colonization of
Streptococcus mutans and reduces the risk of tooth decay (Lehner et al. 1985; Ma et al. 1989; Ma
et al. 1998). New approaches to the treatment of cancer utilize a patient’s own antibodies to
prevent further spread and reoccurrence. In clinical trials, patient idiotype-specific single-chain
variable fragment (scFv) were isolated from the individual patients, sequenced and then ligated
into a plant expression vector and subsequently transiently expressed in N. benthamiana and
injected back into the patients (McCormick et al. 1999; McCormick et al. 2003; McCormick et
al. 2008). Accomplished in only a few months after the initial biopsy, this demonstrates the
utility of green bioreactors to respond to meet the demands for vaccines following the onset of
new epidemics and their utility in treating diseases that require a more individualistic, tailored
therapeutic.
1.3.2 Vaccines
A number of potential vaccines have been produced to date in transgenic plants,
including foot and mouth disease, severe acute respiratory syndrome (SARS), cholera and human
immunodeficiency virus (HIV) (Wu et al. 2003; Huang et al. 2005; Pogrebnyak et al. 2005; Jani
et al. 2004; Marusic et al. 2007; Zhang et al. 2002). Typically this involves the production of a
component of the infectious agent, be it a viral capsid protein fragment or bacterial cell surface
protein. The effectiveness of these recombinant vaccines combined with the attractiveness of
plant-made pharmaceuticals has led to increased commercial interest in recent years, including
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the recent expansion of Medicago Inc., a Quebec City-based company that produces flu vaccines
via transient expression in plants (D'Aoust et al. 2010).
1.3.3 Treatment of autoimmune disease
Autoimmune diseases are the result of the immune system’s failure to distinguish selfproteins from foreign ones, resulting in an immune response against tissues/organs displaying
those proteins. Type 1 diabetes mellitus (T1DM) is an autoimmune disease that results in the
destruction of the insulin producing islet cells of the pancreas, resulting in the individual’s loss of
glycemic control (Ma et al. 1997). In T1DM, there are a number of potential proteins that
become immune targets, with the two most characterized being insulin (INS) and glutamic acid
decarboxylase 65 (GAD65) (Ma et al. 1997; Arakawa et al. 1998; Ma et al. 2004; Li et al. 2006a;
Ruhlman et al. 2007). A potential therapy for T1DM is through the induction of oral tolerance, a
natural process whereby the immune system is disarmed against ingested proteins, attenuating
immune responses against the thousands of harmless dietary proteins that pass through the gut
each day. Oral tolerance can be induced in non-obese diabetic (NOD) mice, a model for T1DM,
by feeding plant tissue expressing GAD65 and an immunomodulatory cytokine, interleukin 4
(IL-4) (Ma et al. 2004). Other targets of the autoimmune response have been evaluated with
similar success, including insulin (Arakawa et al. 1998). Research has also demonstrated that
small antigenic peptides, those amino acid sequences that are targeted by the immune response,
can also prove effective. The small size of these peptides, typically from 5 to 20 amino acids,
typically necessitates fusion with a larger protein. One such example is the production of the B
chain of insulin as a fusion with the non-toxic B subunit of cholera toxin (CTB), resulting in a
large, stable homopentamer (Li et al. 2006a).
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1.4 Plant transformation techniques
1.4.1 Particle Bombardment
Transformation via microparticle bombardment involves the coating of the desired
expression cassette to a microparticle, typically gold or tungsten, and subsequent discharge of a
high pressure burst of helium (Taylor and Fauquet 2002). The subsequent particle-cassette is
hurled towards the target tissue and penetrates plant tissue. In the process, this causes significant
damage to the surrounding tissue. Bombardment can perform a variety of plant transformations,
including transient and stable nuclear, chloroplastic and mitochondrial expression (Taylor and
Fauquet 2002). Biolistic delivery allows for the insertion of minimal expression cassettes, which
are cassettes that contain the gene of interest plus transcription machinery and possibly a
selection marker. A major advantage of this system is that a wide-range of plant species can be
transformed through relatively standardized protocols that are typically difficult transform via
other methods, resulting in transformation of plants such as palm trees, tobacco, tomato and rice
(Parveez et al. 1997; Lutz et al. 2001; Zhou et al. 2008; Lee et al. 2006).
1.4.1.1 Plastid transformation
Plastid transformation via particle bombardment has the greatest potential for
recombinant protein accumulation amongst all plant transformation techniques to date, with
reports of recombinant protein accumulation ranging from under 1% to over 50% of soluble
protein (Lentz et al. 2010; Li et al. 2006b; Ruhlman et al. 2007; Lenzi et al. 2008; Zhou et al.
2008; Soria-Guerra et al. 2009). There are several reasons for the high accumulation potential of
plastids, including multiple copies of DNA per plastid, with mature chloroplasts containing
between 50 to 100 copies of the plastid genome, and ~100 plastids per mature leaf cell (Maliga
2004; Grevich and Daniell 2005). This results in the potential for nearly 10,000 copies of the
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DNA for the production of recombinant protein. In addition, the transformed gene is inserted into
the plastid genome via homologous recombination, allowing for the optimization of insertion
point to suit each expression cassette, something not routinely possible with plant nuclear
genomic transformation. Plastid-based expression also offers a level of environmental
containment, as plastids are maternally inherited and thus is unlikely out-cross through pollen
spread to relative species or untransformed sister crops (Svab and Maliga, 2007).
There are, however, limitations to the use of plastid transformation. Firstly, with nearly
10,000 copies of DNA per cell, selection time is dramatically increased in order to reach a
homoplastic state (point at which all copies of DNA contain the transgene). Second, plastids are
prokaryotic in origin and thus are unable to perform eukaryotic post-translational modifications
such as glycosylation, required for many glycoproteins to function properly and for increased
stability.
1.4.2 Agrobacterium
Recombinant protein expression in plants is also routinely achieved by infecting plants
with Agrobacterium tumefaciens, recently reclassified as Rhizobium radiobacter, a bacterium
that causes crown gall disease in a variety of plants species (Young et al. 2001). Agrobacterium
is able to insert a portion of its plasmid T-DNA into plants cells, which is then transported to the
nucleus and the resulting gene sequences are expressed. Depending on the protocol used, this can
result in the stable integration of the T-DNA into the plant nuclear genome or transient
expression of multiple copies of non-integrated T-DNA (Sparkes et al. 2006). Originally limited
to a relatively low number of species, particularly dicotyledonous plants, a wide-range of dicot
and several monocot plants are now readily transformed via Agrobacterium transformation,
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including tobacco, Arabidopsis, carrot, tomato, potato, cotton, rice, and corn (Rosales-Mendoza
et al. 2011; Zhang et al. 2006; Wesley et al. 2001; Hood et al. 2007).
1.4.2.1 Stable nuclear transformation
Nuclear transformation via Agrobacterium results in the stable and heritable integration
of the transgene into the host genome. There are a variety of advantages to stable nuclear
integration. In the case of an agronomically advantageous trait such as resistance to the
herbicides 2,4-D and BASTA, there is immense value to the resistance being heritable as
opposed to transiently inducing resistance with each generation (Wright et al. 2010; Viegas and
Notani 1993). Another advantage is the nearly unlimited scalability of stable integration with
extremely minimal input following the initial transformation and characterization of a line. This
means that an experiment can transfer from growth chamber to greenhouse or open fields simply
by amplifying the initial characterized lines, without the need to continually transform each
successive generation. There are, however, several major hurdles that have yet to be fully
overcome with stable transformation. First and foremost are the typically low levels of
recombinant protein expression, with accumulation typically less than 0.5% of soluble protein.
Secondly is the risk of environmental spread of the transgene, as nuclear material contained
within pollen could out-cross to either unmodified sister plants or to natural species in proximity
to the open fields. Several groups have generated either male-sterile lines or lines that are
capable of deleting the transgene in pollen, potentially limiting gene transfer as a major concern
(Evans et al. 2005; Feil et al. 2003).
1.4.2.2 Transient expression
The use of Agrobacterium to transiently express recombinant proteins has a variety of
applications from academic research to commercial and pharmaceutical protein production.
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Transient expression has a number of advantages over stable integration, including typically
higher protein accumulation levels (Sparkes et al. 2006). Further enhancement of accumulation
during transient expression can be achieved by co-expressing a suppressor of the plant RNA
silencing machinery through the expression of a viral p19 protein (Voinnet et al. 2003). The
inclusion of p19 expression typically results in an increase of 50-times or greater accumulation
of the protein of interest. Transient expression can also be accomplished in a significantly shorter
period of time compared to stable integration, with typical induction experiments lasting between
3 and 7 days, followed by harvest and isolation, as opposed to typically having to wait 3 to 6
months before sufficient recombinant protein can be harvested from mature transgenic plants.
For example, it was possible for researchers to isolate novel, patient-specific antibody sequences,
clone them, transiently express them and harvest sufficient protein for re-inoculation in under 6
weeks, something inconceivable via stable nuclear integration, which would most likely have
taken between 6 months to a year (McCormick et al. 1999; McCormick et al. 2008; McCormick
et al. 2003). A major drawback associated with transient expression is the high input
requirements, both in materials and personnel, compared to stable integration. This may create
limitations for long-term production of proteins needed in large quantities, but as demonstrated
for the production of patient-specific antibodies, there are still a variety of commercial and
research applications.
1.5 Hurdles in plant bioreactors
As discussed above, plants offer a variety of advantages as bioreactors. There remains a
variety of hurdles, some of which are unique to the type of expression system (transient versus
stable, for example). Others are common to all bioreactors, such as the cost associated with
purification. A third hurdle involves the generation of small protein fragments. As mentioned in
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section 1.3.3, smaller protein fragments, or epitopes, can prove more effective in the induction of
oral tolerance. However, it is extremely difficult to generate short peptides in plants.
1.5.1 Yield
The overall recombinant protein production capacity of a plant bioreactor is dependent on
1) the biomass yield in a given area, 2) the concentration of soluble protein produced by the
individual plant and 3) the relative amount of the recombinant protein produced compared to all
other proteins. Typically, bioreactor research tends to focus on the third point over the first two,
as the majority of species used as bioreactors have already been selected for centuries or even
millennia for maximum yield and quality. As a result, advances are typically expressed in
increase in percent of soluble protein. For example, in work by Patel and colleagues in 2007, the
authors demonstrated an increase of over 90-fold in Il-10 accumulation when Il-10 is fused with
elastin-like polypeptide (ELP) and stably expressed via nuclear transformation. This is an
example of fusion with a more stable protein partner that, in the case of ELP, is also able to
compartmentalize accumulation within specialized protein storage organelles called protein
bodies (Conley et al., 2009b). Organelle-specific localization is also another method for
increasing accumulation, such as the inclusion of the c-terminal tag K/HDEL that results in
endoplasmic reticulum retention (Tremblay et al. 2010b). The selection of the promoter for
expression, what untranslated regions are used, as well as codon usage can all influence the
accumulation of the protein of interest. The gains from these various techniques, however, have
yet to consistently increase production in stably transformed nuclear lines to be truly competitive
against other bioreactors. Chloroplast transformation can meet the demands for high-yield
expression required to be truly competitive, but are incapable of producing glycoproteins,
resulting in an excellent platform for a more limited number of proteins.
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1.5.2 Purification
All bioreactors, regardless of host species or whether they are cell-culture or wholeorganism based, require post-harvest protein purification. In cell culture systems, secretion to the
media can reduce the complexity of purification, but as discussed in section 1.1, have limited
scalability and are more expensive than whole-plant production. For proteins intended for
medicinal use, or that are needed in ultrapure form, the downstream processing can account for
upwards of 80% of the production costs (Walsh 2002). As such, a variety of genetic fusions have
been used to decrease this cost. The inclusion of a repeat histidine tag (His), typically 6 amino
acids long, is perhaps the most commonly used purification tag for laboratory use as it can be
relatively inexpensive on small scales, requiring an immobilized gel such as agar or sephadex
with bound nickel ions to facilitate purification. Under optimized conditions, His purification can
reach nearly 95% purity in secretory bacterial systems, but in plants, rarely achieves high levels
of purity (Terpe 2003). An alternative approach to affinity-based purification is through the use
of ELP. ELP undergoes inverse phase transition with increasing temperature and/or salinity,
resulting in a reversible change in solubility that can be repeated several times in order to remove
contaminating proteins. For example, Conley and colleagues (2009a) demonstrated that ELPfusions could be readily purified using inverse phase transition cycling as well as enhancing
protein accumulation in plants. However, the purification was, at best, reported at 66% of soluble
protein. One proposed explanation is the high quantities of Rubisco, which is involved in
catalyzing the first step of carbon fixation in plants and is the most abundant protein in nature.
The high levels of Rubisco found within green leaf tissue can cause problems with purification
regardless of method used. An alternative possibility is that plants contain proteins that likewise
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undergo phase transition under similar conditions and this may limit the utility of ELP for
protein purification.
1.5.3 Generation of short peptides
In autoimmune disease, the immune response is typically directed against a limited
portion of the targeted protein, short amino acid sequences called epitopes. For example, in
T1DM, the β chain of insulin (InsB), 30 amino acids long, is a well characterized target of the
immune response, while the α chain, a 20 amino acid fragment, is not a target (Weiner 1997).
There are reasons why it is preferable to use only protein fragments containing epitopes, as there
is a lower risk of negative side-affects than might be associated with full-length administration.
For example, full-length INS may lead to the induction of hypoglycaemia if delivered orally (Li
et al. 2006a). However, it is extremely difficult to produce short peptide sequences in plants, as
evidenced by the literature where nearly all reports of short peptide generation are as fusion
partners with larger, more complex proteins. For example, InsB has only been generated as a
fusion with CTB (Li et al. 2006a).
1.6 ATP/ADP transporter
In tubers, energy must be imported into the amyloplasts through the plastidic ATP/ADP
transporter (AATP1) (Tjaden et al. 1998). When AATP1 is overexpressed, tubers accumulate
greater quantities of starch, with one line producing 36% more starch compared to wild-type
(Tjaden et al. 1998). In contrast, when AATP1 is disrupted through the expression of full-length
antisense AATP1, starch is reduced by over 40%. This decrease in starch is associated with a
subsequent decrease in overall tuber biomass accumulation and morphology, with the most
extreme lines in this experiment having tuber total weight per plant at ~70% of wild-type and
producing more but smaller tubers with adventitious budding. In addition, there is a subsequent
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increase in soluble sugars in the antisense lines (Geigenberger et al. 2001; Tjaden et al. 1998).
The changes in tuber biomass and morphology are consistent with other studies that have
knocked down or knocked out genes directly involved in starch biosynthesis, such as ADPglucose pyrophosphorylase (Muller-Rober et al. 1992).
1.7 Soybean Agglutinin
Soybean agglutinin (SBA) is a 32 kDa homolectin found in soybean seeds. Lectins are
proteins that bind to sugar moieties with varying affinity. SBA binds to N-acetyl-Dgalactosamine, a glycan that can be found on the extracellular portions of cell membrane
glycoproteins. The presence of these glycans on the cell surface of red blood cells allows for
SBA to induce agglutination (clumping) of the cells, hence the protein name agglutinin. SBA
accumulates to nearly 2% of the soluble protein in soybean seeds and is typically extracted from
defatted soybean flour (Percin et al. 2009; Lindstrom et al. 1990). The affinity of SBA for its
ligand allows for purification using affinity chromatography, with N-acetyl-D-galactosaminebound agarose or sepharose columns allowing for the efficient and simple isolation of SBA from
other soybean proteins, with typical recovery of high purity SBA ranging around 90% (Percin et
al. 2009).
The makeup of surface exposed glycoproteins varies from cell to cell, allowing for the
use of lectins, such as SBA, to be used to distinguish between cell types based on binding
pattern. For example, SBA has been shown to bind to cell lines derived from two independent
pancreatic cancers, but does not bind to healthy pancreas-derived cells (Nishimura et al. 1993).
SBA binding patterns can help distinguish between stomach cancers with higher survivorship
(SBA+) and those with higher mortality (SBA-) (Terashima et al. 1997). The ability of SBA to
bind to particular cells in suspension has been adapted for use in clinical settings. SBA does not
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bind strongly to healthy lymphocytes, but does to leukemic lymphocytes (Bakalova and Ohba
2003). This allows for the potential in vitro removal of leukemic cells via lectin chromatography
and the return of the healthy lymphocytes to the body.
Recombinant SBA has been produced in a variety of systems, including monkey COS-1
cells, E. coli and tobacco plants (Lindstrom et al. 1990; Adar et al. 1997). The goals of these
studies were to examine either the regulatory elements involved in SBA expression using
tobacco as the platform (Lindstrom et al., 1990) or the involvement of glycosylation in tetrameric
assembly by comparing non-glycosylated SBA (bacterial) versus glycosylated SBA (COS-1)
(Adar et al., 1997). The absence of glycosylation had no impact on SBA’s ability to induce
agglutination, suggesting that glycans are not required. Glycosylation, however, is important for
the stability of SBA (Sinha and Surolia 2005). COS-1 derived SBA appears to have similar
characteristics to native SBA, binding to sugars in a similar pattern and appearing to have similar
glycosylation, but it requires significantly more COS-1 SBA to induce agglutination of red blood
cells compared to native or bacterial-produced SBA, suggesting the COS-1-made SBA does not
retain native SBA binding affinity (Adar et al. 1997).
1.8 Cholera toxin β subunit
Cholera toxin is a secretory protein complex produced by the bacteria Vibrio cholerae
and is the causal agent in cholera. The β subunit of cholera toxin (CTB) is a non-toxic protein
that forms pentamers and is able to bind to GM1 gangliosides, important for both the natural
binding of cholera toxin as well as its potential use as a therapeutic adjuvant (Holmgren et al.
1993). Its ability to bind to GM1 gangliosides offers the potential for CTB to function as an oral
adjuvant, able to bind to epithelial linings of the intestine and be displayed to the peripheral
immune system, resulting in the induction of tolerance (Sun et al. 2010). CTB fusions with
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insulin, either full-length or the β-chain only, have proven effective in delaying the onset of
T1DM in the non-obese diabetic (NOD) mouse model of the disease through oral administration
(Bergerot et al. 1997; Arakawa et al. 1998; Ploix et al. 1999; Sadeghi et al. 2002; Ruhlman et al.
2007). There are, however, considerations in the use of CTB as an adjuvant where long-term
administration is concerned. In mice fed potato expressing CTB-Insulin during a long-term
study, there were detectable levels of mucosal anti-CTB antibodies, potentially neutralizing the
ingested CTB-insulin over the long-term (Arakawa et al. 1998). While this is of concern for
long-term administration, studies have shown that the use of CTB as an adjuvant can greatly
reduce both the amount of protein needed to induce tolerance, as well as the number of doses
required, potentially negating the need for long-term dosage (Sun et al. 2010).
1.9 p277
p277 is the name given for the 23 amino acids 437 to 460 of heat shock protein 60
(HSP60) that has been implicated in T1DM (Elias and Cohen 1994). Early work demonstrated
that p277 was capable of inducing diabetes in standard mice when administered with carrier
molecules (Elias et al. 1995). This study also demonstrated that following an immunological
challenge with p277 and subsequent transient hyperglycaemia, NOD mice were resistant to the
spontaneous development of T1DM, supporting p277 as a possible therapeutic in preventing
diabetes. Follow-up work by the same group demonstrated that administration of p277 to NOD
mice with either no or overt signs of hyperglycaemia resulted in a reduction in islet
inflammation, a marker for the onset of T1DM in NOD mice (Elias and Cohen 1995).
Subsequent phase II clinical trials of the modified form of the peptide (Diapep277 has the
cysteine residues replaced with valine) have been completed and found that relatively few doses
of Diapep277 is required to maintain c-peptide levels, a marker used for tracking the progression
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of the disease, in newly diagnosed patients (Babad et al. 2010). Phase III clinical trials are
currently underway. However, p277 is currently generated chemically, an expensive method for
peptide generation, potentially limiting its deployment following clinical trials.
1.10 Research goals and objectives
The rising demand for recombinant proteins for academic, industrial and medical uses
necessitates the implementation of more effective and efficient bioreactor production. While
green bioreactors are beginning to be recognized as an inexpensive alternative to traditional cell
culture-based systems, they are still limited by low yields for nuclear expressed glycoproteins. In
addition, there is an increased demand for more efficient means of production and purification of
recombinant proteins for both small and large scale production, as well as the development of
more effective recombinant proteins destined for therapeutic use.
The goal of the research presented in this thesis is to create tools to enhance the
effectiveness of plants as green bioreactors and their utility to the end user, reducing the high
costs typically associated with production, those of yield and purification, and increasing the
efficiency at each stage of the line. To achieve this goal, my research focused on three themes: 1)
to increase the yield of soluble recombinant proteins made in transgenic plants, 2) to develop a
simplified, rapid and high-purity recombinant protein recovery system and 3) to examine the
feasibility of generating small therapeutic peptides in green bioreactors for the treatment of
T1DM. To this end, the specific objectives of this project were:
1) To demonstrate the generation of a genetic fusion of CTB with p277 in stably
transformed tobacco and determine if the CTB-p277 fusion remains stable and retains CTB
pentamer formation, important for binding to GM1 gangliosides.
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2) To determine if a minor reduction in starch accumulation in potato tubers could
increase overall yield. To this end RNA induced gene silencing of the AATP1 gene, with the
emphasis during initial screening focusing on biomass yield. The concentration of soluble
proteins as well as the ability to accumulate a recombinant monoclonal antibody in the highest
biomass accumulating knockdown line will also be examined to assess the overall improvement
in recombinant protein production. Also assessed was the long-term viability of the tubers, as an
advantage of tuber-based production is the ability to store recombinant proteins for extended
periods of time.
3) Recombinant SBA was generated both transiently in Nicotiana benthamiana and
stably in potatoes as a first-step towards generating a novel affinity tag system. The recombinant
protein was compared with native SBA to determine if it retained its ligand specificity, ability to
induce agglutination, similar glycosylation pattern and resistance to gastric passage.
4) To validate genetic fusions with recombinant SBA as a novel affinity tag. GFP was
genetically fused to SBA and examined for both in vivo activity (fluorescence), as well as
activity post-purification following the induction of agglutination of red blood cells. The fusion
protein was compared to N. benthamiana-made recombinant SBA for the purpose of determining
purification level and efficiency, as well as agglutination and ligand specificity.
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2.1 Introduction
Peptide p277 is composed of 24 amino acids from the sequence (437-460) of the human
60 kDa heat-shock protein (Hsp60), with the two cysteine residues of the native sequence
replaced by valines (Elias and Cohen 1994). There is accumulating evidence to suggest that like
glutamic acid decarboxylase (GAD), insulin or insulin B chain 9-23 peptide, p277 of the Hsp60
protein is an autoantigen serving as a target of T-cells in autoimmune diabetes in humans and
NOD (non-obese diabetic) mice, and could therefore represent a potentially effective therapeutic
agent for the treatment of autoimmune diabetes. Indeed, a single injection of 100g of p277 in
incomplete Freund’s adjuvant can induce a shift in the cytokine profile of the spontaneous T cell
response from a damaging Th1-type to anti-inflammatory Th2 type, leading to the permanent
arrest of the β cell damage in NOD mice (Elias et al. 1997). Furthermore, p277 was shown to be
effective even when the treatment was initiated in mice that were already clinically diabetic
(Elias and Cohen 1995). The promising results in animal tests have paved the way for clinical
trials for the treatment of Type 1 diabetes with peptide p277. A phase 1 human clinical trial
showed that subcutaneous administration of p277 is safe, causing no adverse side effects in
volunteers with longstanding Type 1 diabetes and with no detectable C-peptide (Cohen 2002),
and phase 2 clinical trial in early onset Type 1 diabetes showed that treatment with p277 halted
disease progression, prevented further destruction of the beta-cells, and prolonged patients'
insulin production (Raz et al. 2001). Presently a phase III human clinical trial is in progress.
Taken together, these results suggest that the human Hsp60 peptide p277 may hold promise for
therapy against Type 1 diabetes.
Oral administration of autoantigens to induce oral immune tolerance represents one of the
most desirable methods for the prevention and treatment of autoimmune diseases. In addition to
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its simplicity and greater patient acceptance, the advantages of oral antigen therapy include
increased specificity, as well as reduced toxic side effects associated with systemic therapy (e.g.,
by injection). Oral administration of autoantigens has been reported to be effective in
suppressing disease development in animal models of autoimmunity, including the NOD mouse
model of Type 1 diabetes (Weiner et al. 1994; Strobel and Mowat 1998). However, the effective
use of oral tolerance in the treatment of human autoimmune disease may critically depend on the
development of mucosal adjuvants and delivery systems to enhance its efficacy (Ma et al. 2004).
Another serious limitation in the clinical application of oral tolerance strategies will be the
potentially huge cost of producing autoantigens, particularly if repeated regular doses are
required to maintain beneficial effects.
Chlolera toxin (CT), which is a major pathogenic agent produced by Vibrio cholerae, is a
potent mucosal immunogen and adjuvant, and most of these activities are retained by the
nontoxic B subunit of CT (CTB). This is in part due to its high binding affinity for the GM1ganglioside receptor present in most cells of the body (Cuatrecassas 1973). CTB has been
demonstrated to be an efficient oral adjuvant for mucosal vaccines (Bergquist et al. 1997;
Czerkinsky et al. 1989). Furthermore, CTB has been shown to induce oral tolerance for linked
antigens. For example, myelin basic protein (MBP) conjugated to CTB prevented or suppressed
experimental allergic encephalomyelitis (EAE), when using lower concentrations of the
conjugate than is usually necessary to induce tolerance with the protein alone (Sun et al. 2000).
Oral administration of insulin or the B chain of insulin conjugated to CTB enhanced oral
tolerance, and reduced the dose of antigen and the administration rate necessary for suppression
of diabetes in NOD mice (Ploix et al. 1999; Sadeghi et al. 2002). Promising results against type
II collagen-induced arthritis have been obtained by intranasal administration of low doses of type
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II collagen-CTB conjugate (Tarkowski et al. 1999).

These results indicate that mucosal

administration of autoantigens conjugated to CTB may represent a useful future treatment
approach for human autoimmune diseases, such as type I diabetes. At the present time, the
mechanism underlying CTB's efficacy as a mucosal adjuvant or carrier molecule has not yet
identified with certainty. It has been speculated that the CTB binding to GM1 increases the
permeability of the membrane to the antigen (Nashar et al. 1996). CTB also induces the major
histocompatibility complex (MHC) class II expression on B cells and significantly stimulates
antigen presentation in macrophages (George-Chandy et al. 2001).
We have developed a new method for inducing oral tolerance, which is based on the use
of transgenic plants such as potato and low-nicotine tobacco to express and deliver recombinant
autoantigens such as murine GAD67 to the mucosal immune system (Ma et al. 1997). Transgenic
plants offer several advantages for an oral tolerance strategy, not the least of which is their high
production potential for relevant autoantigens with nearly unlimited scale up (Kusnadi et al.
1997). As protein purification costs can eliminate the economic advantage of any production
system, an additional advantage of transgenic plants for oral tolerance is that plants can also
become effective delivery systems without extensive purification. Plant expression also largely
eliminates concerns regarding potential pathogens that could be transmitted to humans. Lastly,
augmented immune responses to plant produced vaccines may suggest increased stability for
plant expressed recombinant proteins to gastrointestinal degradation. Collectively these features
make plants an ideal expression and delivery system for oral tolerance. More recently, we have
demonstrated that in addition to synthesizing autoantigens, transgenic plants can be used to
express immunoregulatory cytokines such as interleukin-4 (IL-4), and that combined oral
administration of plant-derived human GAD65 and plant-derived IL-4 had a synergistic effect in
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inducing robust oral immune tolerance in NOD mice, an animal model for human Type 1
diabetes (Ma et al. 2005; Ma et al. 2004).
The aim of the present study was to produce a fusion protein consisting of CTB and the
peptide p277 (CTB-p277) in transgenic plants. Our long-term goal is to develop a plant-based
oral peptide vaccine to treat Type 1 diabetes via the induction of oral tolerance. Here we
demonstrate that the CTB-p277 fusion protein can be efficiently produced in transgenic tobacco
plants. Moreover, the plant-derived fusion protein retains important functional characteristics of
the native CTB, including pentamerization and GM1 ganglioside receptor binding. The
production of transgenic plants expressing the human Hsp60 peptide p277 linked to mucosal
adjuvant CTB offers an important first step towards the development of a safe, effective and
inexpensive vaccine product for Type 1 diabetes
2.2 Materials and Methods
2.2.1 Plasmid construction
An oligonucleotide containing an engineered Xho1restriction site followed by the coding
sequences for the peptide p277 was custom synthesized by commercial suppliers. The
oligonucleotide was rescued by cloning into the HincII site of the pUC 19 vector to generate
pUC19-p277. To create the CTB-p277 fusion protein, the p277 encoding sequence was isolated
from pUC19-p277 as a XhoI and BamHI fragment and cloned into the same sites of pUC19CTB. The plasmid pUC19-CTB contains the ctxB gene with its signal peptide replaced by a plant
signal peptide (i.e., the signal sequence of peanut peroxidase) (Li et al. 2006a). The in-frame
fusion of CTB with p277 was confirmed by sequencing analysis. The fusion gene was isolated as
a NcoI and XbaI fragment and inserted into the same sites of pTRL2-GUS (Carrington and Freed
1990) to replace the GUS gene. The resulting expression cassette comprising the CaMV35S
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promoter with a double enhancer sequence (2x35S) fused to a 5' untranslated tobacco etch virus
(TEV) leader sequence, ctxB-p277, and the nonpaline synthase (NOS) terminator were excised
as a HindIII fragment and cloned onto into the pBI101.1 binary vector to create pRT-CTB-p277.
Plasmid pBI101.1 is a derivative of pBI 101 in which the GUS gene together with the NOS
terminator was deleted. The pRT-CTB-p277 binary vector was transformed into Argobacterium
tumefaciens strain LBA4404 by tri-parental mating (Lige et al. 2001).
2.2.2 Plant transformation
Nicotiana tabacum cv. 81V9 leaf discs were transformed by co-cultivation with A.
tumefaciens LBA4404 containing the pRT-CTB-p277 binary plasmid as described by Horsch et
al (1985). Transformed leaf discs were selected on callus inducing MS104 medium containing
100mg/l kanamycin. New shoots that developed from calli were transferred to magenta boxes
containing MS medium with 50mg/l kanamycin and maintained.
2.2.3 PCR analysis of transgenic plants
Transgenic plant DNA was isolated from leaves of tobacco plants grown aseptically in
Magenta boxes according to Ma et al. (2004). PCR was carried out using forward primer 5’ATGGCACTTCCAATTAGCAAG-3’ (corresponding to codons encoding the N’Terminal
engineered

signal

peptide

sequence

of

CTB)

and

reverse

primer

5’-

TTAGTCCTCATTTGCGGGTGTA AGGGA-3’ (corresponding to codons encoding the Cterminal p277 amino acid sequence) to detect the presence of the ctxB-p277 fusion gene, or
reverse primer 5’-CTCGAGCGGCCCCGGCCCA TTTGCCA-3’ (corresponding to the Cterminal end of CTB) to detect the presence of the ctxB gene. Cycling conditions comprised an
initial step at 94°C for 3 min followed by 30 cycles of 45 s at 94°C, 1 min at 56°C, 1 min at
72°C, and a final extension step at 72°C for 10 min.
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2.2.4 RNA purification and RT-PCR analysis
Plant RNA was purified with RNeasy Plant Mini Kit (Qiagen) following the
manufacturer’s instructions. For RT-PCR, first-strand cDNA was generated in a 20-l reaction
containing 5 g of total RNA, 0.5 g of oligo(dT)18 and 20 units of SuperScript™ II RNase H
Reverse Transcriptase (Invitrogen). A total of 100 ng of RNA-derived first strand cDNA were
then used for PCR reaction using the same primer pair utilized above for the detection of ctxBp277 fusion gene. The polymerase used was Taq DNA polymerase (Amersham). The PCR
cycling conditions were the same as above. RT-PCR products cloned into pUC-19 were
sequenced to confirm full length CTB-p277 expression.
2.2.5 Western blot analysis of transgenic pRT-CTB-p277 plants
Accumulation of the fusion protein in transgenic pRT-CTB-p277 plants was analyzed by
Western blotting. Expanded leaves of tobacco plants were ground by mortar and pestle and
resuspended in extraction buffer (200 mM Tris pH8.0, 100 mM NaCl, 400 mM Sucrose, 10mM
EDTA, 14 mM ß-mercaptoethanol, 1 mM phenyl-methylsulfonyl fluoride, 0.05% v/v Tween-20,
2 µg/ml aprotinin, 2 µg/ml leupeptin). Samples were centrifuged for 10 min at 4 °C and the
supernatant was collected. The concentration of total soluble protein (TSP) was measured
according to the Bradford method using the Protein Assay dye (500-0006, Bio-Rad). Samples
were boiled for 5 min or left untreated, separated by SDS-PAGE and blotted onto PVDF
membrane (Millipore, Burlington, MA). The membrane was blocked overnight in 5% skim milkTBST (20mM Tris, 150 mM NaCl, 0.01% v/v Tween20, pH7.6), then incubated for 2 h in 1:500
dilution (v/v) of rabbit anti-CTB primary antibody (C-3062, Sigma). The blot was then incubated
for 1 h with goat anti-rabbit peroxidase-linked antibody (G-7641, Sigma). Antibody detection
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was accomplished with SuperSignal® West Pico Chemiluminescent Substrate (34080, Pierce,
Rockford, IL). Signals were visualized using a Lumi-imager (Roche Diagnostics).
2.2.6 Quantification of CTB-277 protein accumulation by ELISA
Quantitative ELISA (enzyme-linked immunosorbent assay) determined the level of CTBp277 fusion protein accumulation in transgenic plants as described previously (Li et al. 2006a).
In brief, triplicate serial dilutions of the plant protein extracts and a CTB standard (C-9903,
Sigma) were bound to a 96-well microtiter plate overnight at 4°C. Background was blocked for 2
h in 5% (w/v) skim milk-PBST. Plates were washed with PBS, and then incubated with rabbit
anti-cholera toxin antibody (C-3062, Sigma) at a dilution of 1:1000 for 2 h at 37 °C. Following
wash with PBS, plates were incubated with goat anti-rabbit peroxidase-linked antibody (G-7641,
Sigma) and developed with the Substrate Reagent Pack (DY999, R&D Systems). Optical density
(OD) values were measured at 450 nm, with TSP from untransformed tobacco plants used for
background subtraction, and compared to the standards to determine expression level.
2.2.7 GM1-ganglioside binding assay
The GM1-ELISA assay was performed to determine the binding capacity of plantderived CTB-p277 fusion protein to GM1 ganglioside. Briefly, the microtiter plate coated
overnight at 40C with monosialoganglioside-GM1 (Sigma G-7641) at a concentration of 3 g/ml
(in bicarbonate buffer: 15 mM Na2CO3, 35 mM NaHCO3, adjusted pH to pH 9.6) was blocked
with 3% (w/v) fat-free milk powder in PBS and incubated at room temperature for 2 h, followed
by three washes with PBST. The wells were loaded with protein isolated from transgenic plants,
or bacterial CTB as a positive control. Plates were incubated overnight at 40C. After washing, the
specific binding of plant-derived CTB-p277 to GM1 ganglioside was visualized by the addition
of rabbit anti-cholera toxin antibody (Sigma C-3062; 1: 2000 dilution) followed by enzyme-
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conjugated

anti-rabbit

IgG

(1:5000

dilution)

and

enzyme

substrate

3,3’,5,5’-

tetramethylbenzidine(TMB; Sigma) as for an ordinary ELISA as described above.
2.3 Results
2.3.1 Construction of pRT-CTB-p277 plasmid and plant transformation
The expression vector pRT-CTB-p277, which contains an in-frame fusion of the ctxB
gene and the p277 fragment of human heat shock protein 60, is shown in Fig. 2.1. Construction
of pRT-CTB-p277 has been described in detail in Methods. The fusion gene was under the
transcriptional control of a doubled CaMV 35S promoter.
Following the leaf disc transformation with Agrobacterium containing pRT-CTB-p277,
more than 25 independent transgenic plants were produced. The presence of the fusion gene was
confirmed by PCR analysis of transgenic plants using primers that spanned the entire fusion gene
(Fig.2.2).
2.3.2 Detection of the CTB-p277 fusion gene transcripts in transgenic tobacco plants by
RT-PCR

RT-PCR analysis was employed to detect the expression of the CTB-p277 hybrid mRNA
in transgenic tobacco lines. When primers spanning the full length of CTB-p277 were used, an
amplification product of expected size (480 bp) was detected following reverse transcription of
total RNA extracted from leaf tissues of tobacco lines transformed with pRT-CTB-p277.
Representative data are shown in Figure 2.3. No RT-PCR products were detected using the total
RNA from the wild-type tobacco plants. To rule out the possibility of amplification of
contaminant DNA in the samples, direct PCR amplification without reverse transcription was
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Figure 2.1 Schematic diagram of the plant expression vector pRT-CTB-p277. The T-DNA region inserted into the
plant genome contains the nopaline synthase expression cassette (KanR), which confers kanamycin resistance on
transformed cells, and the CTB-p277 fusion cassette consisting of the CaMV 35S promoter fused to a tobacco etch
virus5’-untranslated region (TEV) and nopalin synthase terminater (Nos-ter). The nucleotide and amino acid
sequences of p277 as well as the sequence surrounding the fusion site are shown at the bottom. The underlined
sequences correspond to the flexible hinge region. The boxed sequences represent the joining site between the two
fusion partners. The stop codon is indicated by an asterisk.
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Figure 2.2 Detection of CTB-p277 integration into transgenic tobacco genomic DNA by PCR. The CTB-p277
fusion gene was amplified from transgenic plant DNA by PCR, and the PCR products were separated by agarose gel
electrophoresis. M, DNA ladder; A, PCR product amplified from pRT-CTB-p277 plasmid DNA with primers
specific for full-length CTB (positive control); B, PCR product amplified from pRT-CTB-p277 plasmid DNA with
primers specific for full-length CTB-p277 (positive control); C, PCR amplification of pUC19-CTB with primers
specific for full-length CTB-p277 (negative control). T1 to T24, independent transgenic lines amplified with
primers specific for full-length CTB-p277. WT, wild-type tobacco amplified with primers specific for full-length
CTB-p277.
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Figure 2.3 RT-PCR analysis of CTB-p277 transcripts in RNA from transgenic plants. Total RNA was extracted
from leaf tissues of individual transgenic lines. RT-PCR reaction conditions were described in Methods. Primers
used were the same as described above for PCR detection of full-length CTB-p277 from plant genomic DNA. M,
molecular size marker; T1 to T4, independent transgenic lines; WT, wild-type tobacco.

39

performed on the RNA preparations. No amplified PCR products were seen under the same
conditions (data not shown), confirming the specificity of the RT-PCR reaction. Sequencing of
the RT-PCR products confirmed the correct full-length in-frame fusion of the CTB-p277 fusion
(Data not shown).
2.3.3 Accumulation of CTB-p277 fusion protein in transgenic tobacco plants
To examine the accumulation of CTB-p277 fusion protein in the transgenic plants,
Western blot analysis was performed. Proteins extracted from leaves of the pRT-CTB-p277
tobacco plants were probed with anti-CTB polyclonal antibody (Fig. 2.4). The anti-CTB antibody
detected a major band of 14 kDa, which is about 2 kDa larger than the control CTB in size, as
well as two minor bands between 19 and 35 kDa when the samples were boiled prior to loading.
The major band was consistent with the expected size of the monomeric form of CTB-p277,
while the two minor bands may represent the dimeric and trimeric forms of CTB-p277,
respectively. When the samples were loaded unboiled, a single 81-kDa band was seen in extracts
from pRT-CTB-p277 tobacco plants but not from wild-type (Fig. 2.4). The 81-kDa band appears
to correspond to pentameric CTB-p277. The presence of a single band suggests that the protein is
stable and assembled as a biologically active CTB pentamer. The same bands could not be
detected when the extracts were probed with anti-human hsp60 monoclonal antibody (data not
shown). This may be due to the low affinity of the anti-human hsp60 antibody towards the
peptide p277.
2.3.4 Quantification of CTB-p277 fusion protein in transgenic tobacco leaf tissues
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Figure 2.4 Western blot analysis of CTB-p277 fusion protein expression in transgenic plants. Total protein extracts
(40 g/lane) from leaf tissues of transgenic plants were fractionated by SDS-PAGE gel, blotted onto PVDF
membrane, and probed with anti-CTB antibody. Both boiled and unboiled samples were analysed. T4 and T24
represent two individual transgenic lines; WT, wild-type tobacco; rCTB, recombinant bacterial CTB standard
(Sigma). Bands for CTB-p277 monomer (single-headed arrow), dimer (double-headed arrow), trimer (triple-headed
arrow) and pentamer (non-tailed arrow) are indicated. Numbers on the left indicate positions of protein size markers
in kDa.
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The levels of CTB-p277 fusion protein expression in transgenic leaf tissues were
determined by ELISA. Using this method, the amount of plant CTB-p277 fusion protein was
calculated by comparison of the optical density (OD) values obtained for transgenic extracts with
the OD values for a known amount of bacterial CTB standard. The amount of the fusion protein
was then expressed as a percentage of the total soluble plant protein (TSP). Representative data
are shown in Fig. 2.5a. Transgenic line T4 showed the highest expression of CTB-p277 fusion
protein, accounting for 0.1% of TSP.
2.3.5 GM1 receptor-binding assays of plant-derived CTB-p277 fusion protein
Biological functions of CTB, such as the ability to bind to GM1 ganglioside, depend on
the formation of a pentameric structure composed of identical monomers (Hardy et al. 1988). To
demonstrate that the plant-derived CTB-p277 fusion protein binds to GM1gangliosides, a GM1ELISA was performed on the leaf extracts from transgenic line T4. The results show that both
plant-derived fusion protein and commercial CTB bind gangliosides efficiently (Fig. 2.5b). No
binding activity was detected when the plate was coated with irrelevant bovine serum albumin
(BSA). These results further suggest that the CTB-p277 pentamer is required for biological
activity. Thus, the addition of the p277 peptide to the C-terminus of CTB protein did not affect
pentamerization or GM1 receptor binding of the protein.
2.4 Discussion
We report here the production of a fusion protein containing the anti-diabetic peptide p277 fused
to the C-terminal of the B subunit of cholera toxin (CTB) in transgenic plants, a first step
towards the development of a plant-based oral peptide vaccine for the treatment of Type 1
diabetes by inducing oral immune tolerance. The human hsp60 peptide p277 represents a
functional important target in Type 1 diabetes, and injection of p277 has been shown to be very
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Figure 2.5 a) ELISA quantification of the CTB-p277 fusion protein. The amount of the CTB-p277 in total soluble
protein (TSP) of transgenic tobacco leaf tissues was estimated by using ELISA as described in the Methods. The
CTB-p277 fusion protein concentration was expressed as a percentage of TSP. Data shown here represent averages
of three experiments. The numbers on the bottom of the figure represent the different tobacco lines. WT: wild-type
tobacco. The error bar represents the standard deviation. b) GM1 binding analysis of plant-derived CTB-p277 fusion
protein. The protein samples used in this assay were prepared from transgenic line T4. The amount of total protein
added to the microplate well coated with GM1-ganglioside or BSA (control) was adjusted to obtain the
concentration of CTB-p277 at proximately 8 ng/ml. The concentration of bacterial CTB used was 10 ng/ml. The
absorbance of the GM1-ganglioside-CTB-p277 complex in each well was measured. The values represent the
averages of three experiments. The error bar represents the standard deviation.
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effective at treating Type 1 diabetes in both humans and NOD mice (Abulafia-Lapid et al. 1999).
However, injection is not the preferred route of administration. Injections can cause discomfort
and distress, and require trained people to administer it safely. This method also risks introducing
harmful microbes into the patient's circulation system. Moreover, as most peptide drugs are
chemically synthesized, the cost of their production is high and mass production would be
difficult. Administration of p277 by the oral route offers practical advantages over parenteral
administration: requiring neither sterile needles nor trained personnel, lower cost, increased
quality of life, reduced side-effects, and greater patient acceptability and compliance. However,
administration of therapeutic peptides by the oral route represents a major challenge. When
administered orally, peptides are subjected to quick degradation by the enzymatic environments
of the gastrointestinal tract and especially by the acidic environment of the stomach, thus
requiring much higher amounts of peptide than subcutaneous injection. To address these
limitations, we have therefore expressed p277 as a fusion with CTB. CTB is a highly stable
protein, and has been shown to be an excellent oral delivery carrier and adjuvant for other
peptide or protein antigens (Holmgren et al. 1993).
As the capacity of CTB as a mucosal adjuvant or carrier molecule for conjugated antigens
is critically dependant on its ability to bind GM1 ganglioside in its pentameric form, it is
essential to ensure that the CTB-p277 fusion protein retained the ability to form pentamers and
bind the GM1 ganglioside receptor. Western blot analysis of unboiled transgenic leaf extracts
with anti-CTB antibody showed that the fusion protein was apparently assembled into a
pentameric structure (Fig. 2.4). Moreover, GM1-ELISA showed that plant-derived CTB-p277
binds to GM1-receptors as efficiently as the native CTB (Fig. 2.5B). These suggest that the p277
peptide carried by the fusion protein had no demonstrable adverse effect on assembly or GM1
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binding of the parental CTB molecule. These results agree with our previous observations that
genetic fusion of human insulin B-chain to the C-terminus of CTB had no detectable negative
effect on pentamerization and GM1-binding capacity of CTB (Li et al. 2006a). Previous work by
Liljeqvist et al. (1997) has suggested that pentamerization and GM1 binding capacity of CTB
linked with proteins or peptides can be affected by the length of the partner protein or peptide, or
by the conformational changes induced by the fusion partner. To minimize any possible negative
perturbation effects of the fusion partner on the pentamer formation and ganglioside-binding
capacity of CTB, the p277 was purposely fused to the C-terminus of CTB, as the GM1 binding
properties of CTB does not critically depend on its C-terminal amino acid sequences (Zhang et
al. 1995). Furthermore, a flexible hinge tetrapeptide (GPGP) was introduced between the CTB
and p277 to reduce potential sterical hindrance and permit high intramolecular flexibility
between the two partners of the fusion protein.
Analysis of boiled transgenic leaf extracts by Western blot using the same anti-CTB
antibody revealed one specific band of about 14, and two bands between 19 to 35 kDa (Fig. 2.4).
The 14-kDa band with the highest intensity was consistent with the expected size for the CTBp277 monomer, whereas the two larger bands may correspond to the CTB-p277 dimer and
trimer, respectively. The detection of both dimeric and trimeric forms of CTB-p277 in boiled
samples suggests that the fusion protein is rather heat stable. The failure to detect the CTB-p277
fusion protein in the same transgenic leaf extracts by using a commercially available anti-human
hsp60 monoclonal antibody (Clone 264233, R&D Systems) is not surprising. As this anti-human
hsp60 antibody was raised against the whole hsp60 protein, it may not have a high binding
affinity towards the peptide p277 that is only 24 amino acids in length. However, two lines of
evidence support our conclusion that plant-derived fusion protein contains the amino acid
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sequence of peptide p277. First, PCR amplification of the genomic DNA isolated from pRTCTB-p277 transgenic tobacco lines resulted in an anticipated 480-bp DNA fragment, when
primers specific for full-length CTB-p277 were used (Fig. 2.2, lanes T1 to T24). The same band
was amplified when pRT-CTB-p277 plasmid DNA was a template using the same primer pair
(positive control) (Fig. 2.2, lane B), whereas no PCR products were obtained when pCU19-CTB
plasmid DNA was amplified with this primer pair (negative control, as this plasmid contains
CTB without p277 sequence) (Fig. 2.2, lane C). On the other hand, an anticipated smaller DNA
band (400 bp) was obtained when pRT-CTB-p277 plasmid DNA was amplified using primers
specific for CTB but not for the fusion gene (Fig. 2.2, lane A), due to the presence of p277
sequence not being amplified. Secondly, RT-PCR amplification of total RNA isolated from these
pRT-CTB-p277 transgenic tobacco lines also gave a 480-bp DNA product when the same CTB
and p277 specific primer was used (Fig. 2.3), suggesting the expression of full-length CTB-p277
mRNA. As anticipated, RT-PCR amplification of total RNA isolated from wild type tobacco
plants gave no product (Fig. 2.3). The in-frame fusion of CTB and p277 was further confirmed
via cloning of the RT-PCR product and DNA sequencing (data not shown). Taken together, these
results provide solid evidence that the fusion protein contains the amino acid sequence of p277.
The expression level of CTB-p277 fusion protein accounted approximately for 0.1% of
total protein in tobacco leaf tissues (Fig. 2.4), which is higher than that reported for CTB or CTB
fusion protein expressed in transgenic tobacco by other groups (Wang et al. 2001; Jani et al.
2004). This may be partly attributed to our use of a plant signal peptide to replace the native
signal of CTB. We have previously shown that the use of a plant signal improves the expression
of CTB in transgenic tobacco (Li et al. 2006a). It is anticipated that the current level of CTBp277 expression can be further improved. One strategy is to express the fusion protein in the
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chloroplast of tobacco plants. Daniell et al (2001) reported the expression of CTB in transgenic
tobacco chloroplasts at levels up to 4.1 % of total soluble tobacco leaf protein. Another strategy
is to express the CTB-p277 as an ubiquitin fusion. Recently, Mishra et al. (2006) demonstrated a
significant increase in accumulation of CTB when it was expressed as an ubiquitin fusion in
transgenic tobacco plants.
In summary, we have produced transgenic plants expressing CTB-p277 fusion protein.
Functional analysis of the plant-derived fusion protein showed that it retains the biological and
immunological characteristics of the native CTB including its ability to pentamerize and to bind
to GM1 ganglioside receptor. Oral administration of transgenic plants expressing high levels of
CTB-p277 may prove to be an effective method for inducing oral tolerance to treat Type 1
diabetes.
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3.1 Introduction
In recent years, there has been a marked increase in demand for recombinant protein
therapeutics, including monoclonal antibodies and vaccines, largely due to a better understanding
of disease pathogenesis and the identification of new molecular targets. On the other hand, it has
become more apparent that the use of conventional cell culture-based expression systems, such
as E. coli and mammalian cells, is difficult to meet the increasing need for therapeutic proteins,
necessitating the development of alternative expression systems capable of satisfying this
demand (Desai et al. 2010). Plants have emerged as a promising alternative to cell culture-based
expression systems for recombinant protein production, offering simple, low-cost growth
requirements, nearly unlimited scalability and a variety of different sub-cellular targeting options
tailored for each protein’s specific requirements, from protein storage vacuoles for cytotoxic
compounds to high-yield non-glycoprotein production in chloroplasts (Tremblay et al. 2010b).
Moreover, being eukaryotes, cells of plants can perform the complex post-translational
modification and processing required by many mammalian therapeutic proteins for biological
and ⁄ or immunological function.
Although many plants can be chosen as host species for the expression of foreign
proteins, potato (Solanum tuberosum) offers a number of advantages as a bioreactor. First and
foremost, potato tubers are natural long-term storage tissues, with a host of protease inhibitor
complexes that have evolved to minimize degradation as the tubers lie dormant (Weeda et al.
2009). Indeed, it was shown that transgenic tubers synthesizing full-size IgGs or Fab fragments
could be stored for up to 6 months without significant loss of antibody amount or activity (De
Wilde et al. 2002). Potato also generates significant biomass compared to other plant production
systems, with an average of over 30 tonnes per hectare according to Statistics Canada
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(statcan.gc.ca). Potato is a vegetable crop with high nutritional value, making it attractive as a
carrier for oral delivery of vaccines and possibly other biologics. There have been an increasing
number of pharmaceutical proteins produced in potato, including cholera vaccines (Arakawa et
al. 1997), human lactoferrin (Chong and Langridge 2000), interleukin-2 (Park and Cheong
2002), hepatitis B surface antigen (Richter et al. 2000), rotavirus capsid protein (Yu and
Langridge 2003), foot and mouth disease antigen (Carrillo et al. 2001), and diabetic autoantigen
(Ma et al. 1997). Although promising, relatively low-level foreign protein accumulation is a
common problem in all plant systems, including potato. It is therefore essential to increase the
efficiency of potato as a bioreactor.
Potato tubers develop at the terminal end of underground stems called stolons and are
major carbon sinks in mature plants. Starch accounts for up to 70% of the dry weight of potato
tubers (Oparka et al. 1990). Alteration of starch biosynthesis has been shown to affect other
biosynthetic pathways in tuber development. For example, inhibition of starch synthesis through
antisense inhibition of its one of the key enzymes, ADP-glucose pyrophosphorylase (AGPase),
results in inhibition of patatin production and, in addition, affects the overall process of tuber
formation, resulting in significantly more tubers per plant (Muller-Rober et al. 1992). Patatin is a
plant storage glycoprotein accounting for up to 40% of the total soluble protein in potato tubers.
Antisense inhibition of plastidic ATP/ADP transporter (AATP1), an adenylate transporter
required for energy import in non-green plastids, results in a decrease in biomass and increased
tuber number (Tjaden et al. 1998). More recently, however, Riewe and colleagues (2009)
reported that altered ATP/ADP balance through the introduction of a plastidically targeted
apyrase results in a 20 to 30% reduction in starch, but with a potential increase in biomass in
lines with the lowest alteration in starch accumulation. Therefore, it is possible that a reduction
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or inhibition of starch synthesis in tubers may provide a new effective strategy for enhancing the
efficacy of potato plants as a bioreactor.
The goal of this research was to determine if potato tuber biomass and total protein levels
could be increased through the disruption of starch synthesis, as we intend to develop new potato
lines with improved efficiency for application as a molecular farming system. To this end, we
utilized a hairpin RNA knockdown approach to disrupt the expression of platidic AATP1 in order
to generate a large number of putative transformants. We identified several riAATP1 lines with
increases in biomass compared to wild-type and selected a single line, designated riAATP1-10,
for further study. The increase in biomass in riAATP1-10 was associated with both an increase in
tuber number as well as in individual tuber size, and with less than a 15% reduction in starch
compared to wild-type. Additionally, riAATP1-10 fresh tubers have an increased soluble protein
concentration compared to wild-type tubers of similar size. We then tested the potential of
riAATP1-10 for use as a new protein expression system. Here we show that when transformed
with a construct containing the gene coding for a human scFv, riAATP1-10 line produced
recombinant protein at expression levels over 0.5% of total soluble protein, a 2-fold increase
over the highest accumulating line in a wild-type background. Together with increased biomass
and increased levels in total protein content, foreign protein expression in riAATP1-10 line
would translate, on the overall, into a nearly 4-fold increase in product yield. Our results indicate
that riAATP1-10 line provides a superior system for recombinant production of foreign proteins,
when potato is chosen as an expression system.
3.2 Materials and Methods
3.2.1 ATP/ADP Transporter RNAi construction
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The theoretical gene structure of S. tuberosum AATP1 was generated by aligning aat1
mRNA (gi:4138582) with Arabidopsis thaliana NUCLEOTIDE TRANSPORTER 1 (NTT1) gene
(gi:844370). The RNAi construct was generated by cloning a portion of the predicted first exon
of AATP1, from base pair 627 to 780 downstream of the predicted start codon, using the primers
F1 F 5’ TCTAGACCATGGTACAGCTTTTGCTGATAAGCTTCTC 3’ with the restriction sites
XbaI,

NcoI

and

underlined,

HindIII

and

F1

R

5’

GAGCTCCTCGAGATTAGCAAATCCCCAAAAGAGTAC 3’, with the restriction sites SacI
and XhoI underlined. The intron from the Patatin gene was also cloned to use as an intron
between

the

inverted

repeat,

using

the

5’GAATTCCCATGGCTCGAGGAATTGGGATCGTAAAAATATTTTG
restriction

sites

EcoRI,

NcoI

and

XhoI

underlined,

primers

PatF

3’,

with

the

and

PatR

5’

AAGCTTTCTAGAGAGCTCTTCGAACCCAATTTCCCAACTGACTCGAAAAGAAAAATA
AGTCG 3’, with the restriction sites HindIII, XbaI and SacI underlined. The restriction sites
were added to each primer to facilitate the assembly of the inverted repeat. The gene fragments
were cloned into pUC19, confirmed by sequence analysis, digested and ligated together and
sequenced again to confirm the correct assembly of the inverted repeat. The entire cassette was
then digest with NcoI and XbaI and ligated into pRTL2 in place of the GUS gene (Carrington
and Freed 1990). The expression cassette was then digested with HindIII and ligated into pBI
101.1 to create pBI-F1IR. The pBI-F1IR was transferred to Agrobacterium via tri-parental
mating (Ma et al., 2005).
3.2.2 scFv construct
The construct bearing the monoclonal antibody, pMB 5-61, was a gift from Klaus Dϋring
(Axara Consulting, Frechen, Germany). The binary vector contained the monoclonal human scFv
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L1G6 antibody with a C-terminal c-myc tag and a 6xHis tag and hygromycin B as a selectable
marker. The plasmid was provided in Agrobacterium and was used directly for plant
transformation as described below.
3.2.3 Potato transformation and growth
Potato mini-tubers (var Désireé) were generated from sterile stocks as previously
described (Bourque et al. 1987). Mini-tuber transformation was carried out using overnight
cultures of Agrobacterium containing the pBI-F1IR plasmid or pMB 5-61 as previously
described (Ma et al. 2005). Briefly, mini-tubers were peeled and cut into 5 mm discs. The discs
where then submerged in MSO (4.4 g/L Murashige and Skoog basal media, 15 g/L Sucrose) in
Petri plates. Agrobacterium cultures were centrifuged for 10 minutes at 1,000g in 1 mL aliquots,
rinsed with MSO 4 times and then a single aliquot was added to the disc/MSO plates. After 30
minutes, discs were dried on sterile filter paper and placed on non-selective regeneration media
(for 1 L add 4.4 g Murashige and Skoog basal media, 30 g Sucrose, 0.5 mg Nicotinic acid, 1 mg
Thiamine HCl, 0.5 mg Pyridoxine, 8 g Phytagel, autoclave 20 minutes, add 2.5 µM Zeatin
riboside, 4.8 µM IAA), covered in foil and incubated for 3 days in the growth chamber.
Following incubation, discs were rinsed with MSO and transferred to regeneration media with
the appropriate selective antibiotic (200 µg carbenicillin with either 50 µg/L kanamycin or 25
µg/L hygromcyin). Regenerating plantlets were transferred to Magenta boxes containing MS
agar (4.4 g/L Murashige and Skoog basal media, 15 g/L Sucrose, 4 g/L Phytagel, pH 5.7)
supplemented with 50 ug/L kanamycin for the pBI-F1IR selection, or 25 ug/L hygromycin for
the scFv work. PCR was used to confirm successful transformation and positive plants were used
to induce mini-tubers. Mini-tubers were screened via RT-PCR for the presence/absence of aatp1
expression (described below) and those that lacked detectable levels were transplanted to soil
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and transferred to the greenhouse along with wild-type desiree. Greenhouse potato plants were
grown for ~3 months until the leaves began to die off, at which point tubers were harvested and
either used immediately for experimentation or stored in the dark at room temperature for use as
tuber seed stock. Each individual plant was harvested separately, with tuber number and biomass
determined at the time of collection, as well as notation of changes in leaf scar number and
photographs of any morphological differences compared to wild-type.
3.2.4 RT-PCR screening
Mini-tubers from independent transformants were screened for the expression of aatp1
using RT-PCR. Total tuber RNA was extracted using the RNEasy Plant Mini Kit (Qiagen
#74903) according to the manufacturer’s instructions. RNA was converted into cDNA using
Superscript II Reverse Transcriptase (Invitrogen #18064) according to the manufacturer’s
instructions. aatp1 was amplified using primers designed to span the predicted first intron: F1 F
(sequence above) and F2 R 5’ CAACATCGATTGCTGCCTTCC 3’. The expression of tubulin
was used as a control: TubF 5’ AATGTGCAGAACAAGAACTCATCC 3’ and TubR 5’
CATAACAAGTTCACTTTGGCAG 3’. PCR conditions were 10 minutes at 94 oC, 30 or 37
cycles of 2 minutes at 94oC, 30 seconds at 60oC, 2 minutes at 72oC, followed by 10 minutes at
72oC.
3.2.5 Starch analysis
Starch quantification was carried using the Starch Assay Kit GO/P (Sigma, STA20-1KT)
according to the manufacturer’s instructions, with corn starch used as a control. Individual lines
were compared against wild-type, with starch extracted from a transverse slice through peeled
potatoes between 20 to 30 mm in length, with the exception of riAATP1-47 as there were no
tubers over 15 mm, and each line was sampled in triplicate.
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3.2.6 Protein extraction
Protein was extracted as previously described (Tremblay et al. 2010a). Briefly, potato
leaf and tuber tissue was ground using a mortar and pestle with the addition of 3 times volume
protein extraction buffer (200 mM Tris pH 8.0, 100 mM NaCl, 400 mM Sucrose, 1 mM
phenylmethylsulfonyl fluoride, 10 mM EDTA, 14 mM β-mercaptoethanol, 0.05% (v/v) Tween20, 2 µg/mL leupeptin, 2 µg/mL aprotinin). The samples were incubated for 30 minutes on ice
and spun at top speed in a micro-centrifuge for 10 minutes at 4oC. The supernatant was collected
and quantified for total soluble protein concentration using the Bradford method (Bradford 1976)
in triplicate and subsequently used for protein analysis.
3.2.7 Protein analysis
Total soluble proteins were loaded onto a 12.5% (w/v) SDS-PAGE gel. Following
separation, gels were either transferred to PVDF membrane for Western blotting or stained with
Coomassie blue for protein profiling. For Western blot analysis of recombinant c-myc tagged
scFv L1G6 expression, the blots were blocked with 5% milk (w/v) in TBS-T, washed 3 times in
TBS-T for 5 minutes and then incubated with 1:1000 mouse anti c-myc (Santa Cruz
Biotechnology Inc. #sc-40) in 1/3 block:2/3 wash buffer overnight at 4oC. The blots were then
washed for 3 times 10 minutes, and then treated with 1:5000 goat anti-mouse HRP for 1 hour at
room temperature. The blots were then treated with SuperSignal West Pico Chemiluminescent
Substrate (Thermo Scientific #34080) and imaged using film.
3.2.8 scFv quantification
The amount of accumulated recombinant c-myc tagged human scFv L1G6 in S
tuberosum tubers for both wild-type and riAATP1-10 was quantified by enzyme linked
immunosorbent assay (ELISA). Briefly, commercially available c-myc protein standard (Abcam
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#84132) and triplicate samples of untransformed wild-type (negative control), pMB 5-61 in wildtype or riAATP1-10 background were bound to 96 well plates by incubation in phosphate buffer
overnight at 4oC. The plates were washed with PBS-T and blocked with 3% BSA in PBS-T for 1
h at room temperature. The plates were then washed 3 times and incubated overnight at 4oC in
1:2,000 mouse anti c-myc in ½ blocking:½ wash buffer. The plates were then washed 3 times
and incubated for 1 h at room temperature with 1:5,000 goat anti-mouse-HRP in ½ blocking : ½
wash buffer and then rinsed 3 times. The plates were incubated with Substrate Reagent Pack
(R&D Systems # DY999) according to the manufacturer’s instructions. The color was developed
for 20 min and then stopped with the addition of 2 M H2SO4. The plate was read using a
Thermomax microplate reader (Molecular Devices, USA). Standard curves were calculated and
used to determine scFv concentrations of the individual samples.
3.3 Results
3.3.1 Generation of knockdown AATP1 lines
A 150 bp sequence of the 3’ end of the predicted first exon of AATP1 gene, as determined
through a comparison of the aatp1 mRNA sequence with Arabidopsis thaliana NTT1 genomic
sequence, was selected and amplified by PCR (Figure 3.1a). A sense and antisense sequence of
the cloned AATP1 fragment were ligated with each other, separated by the first intron of the
patatin gene from S. tuberosum and the expression was placed under the control of a constitutive
35S promoter (Figure 3.1b). The intron was included as this approach has been shown to be more
efficient than either simple loop or directly linked inverted repeats (Wesley et al. 2001). Putative
transformed plantlets were generated following tuber disc transformation via Agrobacterium, and
transferred to rooting medium for shoot elongation and root development. Explants from in vitro
grown plants were cultivated on microtuber inducing medium for the induction of minitubers. In
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Figure 3.1: Construction of the riAATP1 knockdown lines. a) Alignment of S. tuberosum aatp1 mRNA and the A.
thaliana NTT1 gene. Gene structure for NTT1 is displayed at top. Arrows indicate position of primers used for
amplification. b) The cloned aatp1 sequence was ligated to the 1st intron from the PATATIN gene in both sense and
antisense directions. The entire casette was cloned into the pBI expression vector, conferring kanamycin resistance
in plants. c) RT-PCR to confirm aatp1 knockdown. Expression of tubulin was used as a control for RNA quality and
quantity. Single arrow and double arrow indicate positions of 500bp and 650bp marker bands, respectively.
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vitro grown microtubers were screened via RT-PCR to confirm knockdown of aatp1 expression
(Figure 3.1c). Among over 60 independent transgenic lines screened, 47 lines showed an absence
of aatp1 expression following 30 PCR cycles, but in the majority of the samples screened, a faint
product was detected following 37 cycles (data not shown). The 47 transgenic lines were then
transferred to soil in the greenhouse and grown for 3 months to screen for changes in tuber
biomass. There were no observable changes in above ground biomass accumulation or
morphology.
3.3.2 riAATP1-10 has increased tuber biomass
Tubers were harvested following the senescence of above ground biomass, about 3
months post-transplantation. Each potato line was harvested independently and the fresh tuber
weight was compared to highest accumulating wild-type control plant transferred to greenhouse
at the same time (Figure 3.2a). Under identical growth conditions, 5 lines showed an increase in
tuber biomass production compared to that of wild-type, with the transgenic line riAATP1-10
yielding the highest relative biomass. Tubers from riAATP1-10 were used as stock for a second
3 month growth cycle along with wild-type tubers. Each plant was harvested independently and
the tubers weighed, with riAATP1-10 producing nearly 30% more biomass on average than
wild-type, as well as a greater number of tubers (Figure 3.2b,c).
The increase in biomass was not strictly associated with increased tuber number,
however, as when we examined the average biomass of the 4 largest tubers from both wild-type
and riAATP1-10, we found significantly heavier tubers from riAATP1-10 plants (Figure 3.2d,
P<0.05). This suggests that the increase in biomass is a combination of both increased tuber
number as well as an overall increase in tuber size.
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Figure 3.2: Biomass accumulation analysis. a) Tuber biomass accumulation of 47 independent riAATP1 lines.
Dashed line represents the maximum accumulation of wild-type plants grown at the same time. b) Average tuber
biomass accumulation of riAATP1-10 compared to wild-type (Wt). c) Average tuber number per plant for riAATP110 compared to wild-type. d) Average biomass for the 4 largest tubers from both riAATP1-10 and wild-type. * =
significant difference (p>0.05), n = 6 (Wt), 5 (riAATP1-10) for b,c,d.
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3.3.3 Morphological changes in riAATP1-10 tubers
Tubers were also markedly different in morphology compared to wild-type. As seen in
figure 3.3a, the 4 largest riAATP1-10 tubers appear darker in colour, with a reddish hue
compared to the largest 4 wild-type tubers. In addition, the tubers have an increased number of
leaf scars, with nearly twice the number per tuber on average (Figure 3.3b). This trend holds true
when tubers of identical length are examined (data not shown). As expected with an increase in
biomass, there are differences in the tuber dimensions. The riAATP1-10 tubers are significantly
longer than wild-type (Figure 3.3c) but have similar radial dimensions (data not shown). Indeed,
regardless of the size of tuber examined, riAATP1-10 tubers are typically longer than wild-type
tubers with similar radial dimensions. Conversely, tubers from the lowest biomass line,
riAATP1-47, had a greater number of smaller tubers, with each tuber have multiple tuber
nodules forming at within each leaf scar (data not shown).
3.3.4 riAATP1-10 has decreased starch
The plastidic AATP1 is involved in starch production through the importat of ATP into
heterotrophic plastids (Emes and Neuhaus 1997). Previous knockdown of AATP1 using antisense
approach resulted in a range of starch reduction, with a 20% reduction resulting in slightly lower
biomass than wild-type and nearly 50% less starch yielding nearly 25% less biomass, although
this study was limited to 4 individual transformants (Tjaden et al., 1998). As riAATP1-10 had an
increase in biomass, we examined the quantity of starch in this line order to determine if starch
level is disrupted, and to what degree. Starch extraction and quantification of riAATP1-10 tubers
showed a 15% reduction in starch levels compared to wild-type tubers (Figure 3.4).

63

Figure 3.3: Morphological changes in riAATP1-10. a) Picture of the 4 largest wild-type tubers (left) and riAATP110 (right). Bar = 1 cm. b) Box plot of the number of leaf scars per tuber for the 4 largest wild-type (Wt) and
riAATP1-10 line. c) Box plot of average tuber length for 4 largest tubers from wild-type and riAATP1-10 line. * =
significant difference (p>0.05).
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Figure 3.4: Starch accumulation of riAATP lines. Accumulation is present as percent of starch accumulation against
the average accumulation of wild-type tubers from the same experiment (n=3, ± S.E.M.).
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3.3.5 riAATP1-10 has an altered protein profile
We next examined the protein profile of tubers derived from riAATP1-10 potato line in
comparison to wild-type. As shown in Figure 3.5a, notably altered are the bands that correspond
to the expected size for patatin, which can accounts for up to 40% of the total soluble protein in
potato tubers, or for PKPI, a 20 kDa potato Kunitz-type protease inhibitor (Weeda et al. 2009).
There was also a protein band for an unknown protein(s) in riAATP1-10 lines that appears
stronger than wild-type. We also noted similar alterations in the protein profile of the other
riAATP1 knockdown lines (data not shown). Further differences were seen in between wild-type
and riAATP1-10 line when we examined the amount of soluble protein per tuber. There was no
statistical difference in protein concentration between either wild-type or riAATP1-10 in tubers
between 5 and 10 mm in length (figure 3.5b). Soluble protein concentration remains similar for
riAATP1-10 lines regardless of tubers size while the concentration in wild-type tubers decreases
by an average of 34% as the tubers increase to over 30 mm in length (p>0.05). We also examined
the effect of cold storage on the stability of the soluble proteins. riAATP1-10 tubers have nearly
50% less protein on average after 5 months of cold storage, while wild-type lost less than 10%
on average over the same time period (Figure 3.5c).
3.3.6 riAATP1-10 accumulates more recombinant scFv than wild-type
We examined the potential uses of riAATP1-10 as a new potato line to improve
recombinant protein expression due to its increased biomass accumulation and soluble protein
concentration. We selected a human scFv for testing as monoclonal antibodies represent an
increasingly important class of therapeutic agents that are in high demand. To this end, we
transformed both wild-type and riAATP1-10 with human L1G6 scFv (Figure 3.6a). Initial
screening was performed on the leaf tissue, but there was no difference in maximal accumulation
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Figure 3.5: Protein accumulation in tuber lines. a) Protein profile of tubers from 3 wild-type and 3 riAATP1-10
plants. Numbers on left indicate protein standard sizes (kDa); arrow/arrowheads mark major protein band
differences between wild-type and riAATP1-10. Arrow indicates position of the expected size for the patatin
protein; arrowhead for the expected size for the PKPI protease inhibitor; dashed arrow indicates unknown protein.
20µg of TSP loaded per lane b) Comparison of concentration of total soluble protein from freshly harvest tubers
with lengths between 5 and 10 mm or 30 to 50 mm (n=10 each). c) Comparison of concentration of total soluble
protein from 30-50 mm tubers either post-harvest (fresh) and after 5 months cold storage (5 months) (n=10 each). *
= significant difference (p>0.05).
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between the wild-type and riAATP1-10 backgrounds (Figure 3.6b). Following the screening of
72 transformants in the wild-type background, we found a maximal accumulation of the antibody
in the tubers of 0.25% of TSP (Figure 3.6c,d). We screened 20 individual transformants in the
riAATP1-10 background and found that in addition to an increase in maximal accumulation,
with one line yielding a 1-fold increase to over 0.5% of TSP (Figure 3.6c,d). In addition, the
range of scFv accumulation in riAATP1-10 lines was found to be higher overall (Figure 3.6e).
3.4 Discussion
We have demonstrated that through the disruption of starch synthesis it is possible to increase the
efficiency of recombinant protein production in potato tubers. The disruption of starch synthesis
was achieved by using RNAi technology to knock down the activity of the plastidic ATP/ADP
transporter AATP1. Using this technology, we were able to generate a much larger number of
AATP1 knockdown transformants than previously possible when antisense methods were used,
and the resulting screen yielded a variety of biomass accumulation. One such line, riAATP1-10,
produces nearly 30% more biomass per plant with nearly 50% more soluble proteins in larger
tubers, and accumulated just over 100% more recombinant scFV antibody as a percent of TSP
compared to wild-type. Together with increased biomass yield and increased levels in total
protein content, there is potential for a nearly 4-fold increase in recombinant protein production.
Perturbation of starch synthesis can have profound and drastic impacts on tuber
development, as the degree of alteration of the carbon balance between starch and soluble sugars
is important in maintaining tuber sink strength (Oparka et al. 1990). When starch synthesis is
almost completely abolished, tubers have a drastic increase in soluble sugars and each plant
produced many more tubers but had significantly lower overall tuber biomass per plant
compared to wild-type (Muller-Rober et al. 1992). Previously reported knockdown of AATP1
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Figure 3.6: Comparison of scFv production in wild-type versus riAATP1-10. a) Expression cassette for scFv L1G6
under the control of a 35S promoter and with a linked c-Myc tag. The hpt-B gene was included to allow for
hygromycin selection. b) Western blot of expression of L1G6 in leaves of top expressing wild-type backgrounds and
a range of riAATP1-10 plants (20 µg TSP loaded). c) Western blot of expression of L1G6 in tubers of top
expressing wild-type backgrounds and a range of riAATP1-10 lines (20 µg TSP loaded). d) L1G6 accumulation in
top wild-type and riAATP1-10 lines (± S.E.M., * = significant difference (p>0.05)). e) Diagram of scFv
accumulation levels in wild-type and riAATP1-10. The range of plant accumulations are divided into 0.05% of TSP
intervals, with the y-axis representing the percentage of plants within that interval. n=72, 20 for wild-type and
riAATP1-10, respectively.
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using antisense methods resulted in a less drastic decrease in starch content, with up to a 40%
reduction in amylose, but as with starch abolishment, researchers also noticed an increase in the
number of tubers and decrease in overall weight compared to wild-type (Tjaden et al. 1998).
However, relatively few lines were screened and with the primary focus on starch quantification.
In our work, we focused instead on biomass and screened a large number of individual
transformants. We likewise noted an increase in tuber number and typically lower biomass
accumulation in about 80% of the lines. Several lines, however, demonstrated an increase in
biomass during the initial screening, with riAATP1-10 having the greatest increase in biomass
compared to wild-type. In riAATP1-10, we noted a decrease of nearly 15% in starch
accumulation, while those lines with biomass lower than wild-type had significantly greater
starch disruption. This suggests that there may be a threshold for perturbation of the balance
between starch and soluble sugar accumulation, where small reductions in starch production are
sufficient to maintain sink strength while at the same time allowing for higher biomass
accumulation due to the increase in available energy in the form of soluble sugars.
The increase in tuber biomass for riAATP1-10 appears to be a combination of both an
increase in tuber number and individual tuber biomass. When we examined the four largest
tubers from wild-type and riAATP1-10, we found that the increase in tuber biomass appears
linked with an increase in tuber length as opposed to radial width, as the largest tubers all had
very similar radial dimensions, regardless of whether wild-type or riAATP1-10. When
examining the protein expression profile of the transgenic tubers, the reduction in bands
corresponding to patatin and to the protease inhibitor complex appears similar to previous
knockdown of AGPase, although in that case the disruption of starch was significantly more
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severe, as was the resulting protein profile disruption (Muller-Rober et al. 1992). Based on this
profile, it is possible that the tubers are remaining in a post-initiation stage of development. This
can be seen when comparing the protein profile we observed with previously published reports
demonstrating the initiation of patatin and protease inhibitors produced during development
(Weeda et al. 2009). The protein profile for riAATP1-10 is reminiscent of early stage tuber
development, just prior to tuber bulking when wild-type tubers begin to accumulate higher
percentages of patatin and various protease inhibitors.
Soluble protein production in wild-type tubers of S. tuberosum declines as tubers enter
the bulking stage of development (Weeda et al. 2009). At the same time, proteolytic degradation
declines as tubers increase in size, with large tubers having over 50% of soluble protein
committed to a variety of protease inhibitors. This increase in protease inhibitors is one potential
reason for the high stability of recombinant proteins produced in tubers, even months postharvest (De Wilde et al. 2002). We found a similar decrease in soluble protein in our wild-type
tubers, with the largest tubers having 34% lower protein concentration than the smallest tubers
examined. In opposition to this, riAATP1-10 tubers retained the same protein concentration
through tuber expansion, with no difference between small and large tubers. The lower quantities
of the protease inhibitors found in large riAATP1-10 tubers do appear to have a negative impact
on long-term storage of riAATP1-10 tubers. After 5 months of storage, we found nearly half the
amount of soluble protein in large riAATP1-10 tubers, while wild-type lost a small fraction of
this amount. The higher rate of protein turnover in riAATP1-10 may thus make it unsuitable for
long-term storage, although this should not present a major problem for its use as a bioreactor, as
typical post-harvest processing would take place with minimal delay, unlike post-harvest
consumption of potato as a food staple.
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The level of recombinant scFv produced in the riAATP1-10 line is significantly higher
than that achieved in the wild-type background. While the level of expression, just over 0.5% of
total soluble protein, is significantly less than that for production in high yield chloroplastexpression systems, this system offers a number of significant advantages. While reports have
claimed accumulation of over 50% TSP for recombinant production, they are unable to produce
glycoproteins (Cardi et al. 2010). While the requirements for glycosylation vary from
glycoprotein to glycoprotein, they typically are important, at least in part, for protein stability
and resistance to degradation. Genomic expression in eukaryotic potato tubers can achieve
significant recombinant glycoprotein yields.
In summary, we have developed riAATP1-10 as a new potato line for use as a molecular
farming system, offering combined advantages of increased biomass yield and increased total
protein levels. We have demonstrated its efficacy as well as its potential value in expressing a
human scFv antibody. It is expected that the riAATP1-10 line will also be highly valuable for
producing many other therapeutic proteins.
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4.4 Introduction
Soybean agglutinin (SBA) is a legume lectin glycoprotein that binds non-covalently to
specific cell surface carbohydrates, provoking agglutination of the bound cells when in solution.
SBA has been used to fractionate different cell types for use in clinical and biomedical
applications. One such application is the separation of pluripotent stem cells from human bone
marrow. Cells fractionated by SBA do not produce graft versus host disease (GVHD) and can be
used in bone marrow transplantation across histocompatibility barriers (Yura et al. 2008).
Another application is the enrichment and isolation of fetal cells from the blood of pregnant
women as a means to detect fetal genetic and chromosomal abnormalities. It was shown that the
number of fetal erythroblasts recovered by a soybean agglutinin galactose-specific lectin method
was approximately eightfold higher than the number obtained by a standardized magnetic cellsorting (MACS) protocol (Babochkina et al. 2005). In addition, SBA binds very effectively to
certain tumour cells and has been used to detect and treat several cancers including breast cancer
(Pusztai et al. 2008). SBA and other lectins, which are carbohydrate-binding proteins that bind
sugar residues reversibly and specifically, have also been exploited as a ligand for targeted oral
drug delivery as their glycoprotein and glycolipid targets are integral parts of the enterocyte
membrane (Smart 2004). Protocols for high recovery and purity of SBA have been developed,
with extraction of SBA from soybean flour resulting in high quality purification with over 90%
yield (Percin et al. 2009), opening the door for the use of recombinant SBA as a potential novel
affinity tag for purification of genetically fused proteins. The potential production of a variety of
recombinant proteins genetically fused to SBA, however, necessitates the generation of an
efficient recombinant production system.
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Native SBA is produced in the developing seeds of Glycine max, with maximal
production in seeds reaching over 2% TSP (Lindstrom et al. 1990). It is relatively simple to
obtain large amounts of purified native SBA given that soybean seeds express high levels of
native SBA together with the establishment of efficient purification methods. However, many
potential applications of SBA in biotechnology and medicine could not be achieved or are
difficult to achieve with the use of unmodified native SBA. For example, it is difficult to use
native SBA as an affinity tag for protein purification, unless the target protein is genetically
fused to SBA and produced as a recombinant fusion protein. SBA has previously been expressed
in transgenic tobacco seeds in order to study the upstream and downstream cis-regulatory
sequences mediating the expression of native SBA (Lindstrom et al. 1990). Although a protein
band with a molecular mass expected for the monomer of SBA protein was seen on Western
blot, no analysis or characterization of the recombinant protein itself was performed, merely
using it as a marker for gene expression. Others have successfully expressed SBA in both E. coli
and monkey BS-C-1 cells in an attempt to generate recombinant SBA in order to analyze the
relationship between glycosylation and tetramer assembly (Adar et al. 1997). They demonstrated
that the recombinant SBA retained its agglutination ability and specificity for Nacetylgalactosamine. The SBA generated in bacteria, however, lacks glycosylation that, while
not required for agglutination or assembly, is important in the stability of the bioactive tetramer
(Sinha and Surolia 2005). Production in BS-C-1 cells resulted in a similarly glycosylated protein
to native SBA with an identical sugar binding profile but for some unknown reason had a lower
agglutination ability. The minimal amount of BS-C-1 cell derived SBA required to induce
hemagglutination is 10-20 µg/ml, which is 4-5 times larger than that of native SBA. In addition,
for production of a therapeutic protein, animal cells carry an inherent risk of pathogen
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contamination and have a high production cost due in large part to media costs. Therefore, both
bacteria and mammalian cells are not ideal bioreactors for the SBA production for therapeutic
uses.
Plants offer a suitable alternative expression system for recombinant SBA production. As
bioreactors, plants permit unlimited scalability, elimination of product contamination by
mammalian pathogens, as well as reduced production costs compared to microbial or animal
cell-based systems (Ma et al. 2008; Boehm 2007; Tremblay et al. 2010b). Due to their eukaryotic
nature, plants can perform the complex post-translational modification and processing required
by many transgenic therapeutic proteins for biological and/or immunological function.
Furthermore, plant bioreactors offer the short turn-around time to obtain gram quantities of a
recombinant protein in a matter of weeks when expressed transiently. This is not only
economically advantageous, but is also critical to meet challenges related to quick access to lifesaving biotechnology drugs and therapies. In addition, stable edible transgenic plant tissue offers
the possibility of allowing direct oral delivery of plant-derived therapeutic proteins and peptides,
eliminating the need for expensive downstream protein purification and processing.
Our long-term goal is to generate recombinant SBA for use as a carrier molecule for oral
delivery of protein and peptide drugs and as an affinity tag for simplified and high-yield, high
purity isolation of recombinant proteins. As a first step toward these goals, we report here the
transient production of recombinant SBA (rSBA) in Nicotiana benthamiana (Nb), a close
relative of tobacco (Nicotiana tabacum), and stable production in Solanum tuberosum (St) under
the control of a ubiquitous CaMV35S promoter. We demonstrate transient expression of SBA in
Nb plants at levels as high as 4% of total soluble protein (TSP), whereas its stable expression in
St tubers reaches 0.3% TSP. Furthermore, NbrSBA and StrSBA are similarly glycosylated
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compared to native SBA, retain their ability to induce hemagglutination, bind specifically to Nacetylgalactosamine, are stable in simulated gastric fluid (SGF) containing pepsin at acidic pH
and are rapidly isolated to a high degree of purity from total soluble protein.
4.2 Materials and Methods
4.2.1 Plasmid construction
The cDNA of soybean agglutinin (SBA) was cloned from Glycine max cDNA derived
from 1-5mm developing seeds. In brief, total messenger RNA was extracted from the seeds using
the RNeasy Plant Mini Kit (QIAGEN #74903) and converted to cDNA following the Superscript
II

protocol

(Invitrogen

#18064).

AATCCATGGCTACTTCAAAGTTGAAAACC

The
3’

primers
and

F
R

TCTAGATTAATGATGATGATGATGATGGATGGCCTCATGCAACACAAAACTTG

5’
5’
3’

with the addition of a 6XHis-tag to the C-terminus underlined, restriction sites bolded and a
silent mutation to remove an internal HindIII site italicized, were constructed using the
previously published sequence for SBA (Genbank Accession #K00821.1). The generated SBA
cDNA was then inserted into pUC-19. After confirmation by sequence analysis, the SBA cDNA
was inserted into pRTL-2 via digestion with NcoI and XbaI, replacing the GUS gene, providing a
35S promoter, 5’ and 3’ UTR (Carrington and Freed 1990). The resulting expression cassette
was digested with HindIII and inserted into pBI-101 to create pBI-rSBA. Tri-parental mating
was used to transfer pBI-rSBA to Agrobacterium tumifaciens strain LBA4404 and confirmed via
PCR using specific primers.
4.2.2 Transient expression of SBA in N. benthamiana
Transient expression of pBI-rSBA was accomplished through infection of 6-8 week old
leaves of Nicotiana benthamiana as described in (Sparkes et al. 2006). Briefly, overnight
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cultures of Agrobacterium were grown until cell density reached 0.5-1.0 OD600, at which time
the cells were centrifuged at 800xg for 10 minutes, rinsed 4 times with infiltration media (0.5%
w/v D-glucose, 50mM MES, 2mM Na3PO4, 0.0001M Acetosyringone) and then resuspended to
the desired cell density, between 0.01 to 0.75 OD600. The cells were then infiltrated into the
abaxial side of the leaves using a 1mL syringe and infected tissue was harvested each morning at
day 1 through 9 post-infection. For co-infiltration with a second Agrobacterium harboring the TDNA vector encoding the p19 suppressor gene of tomato bushy stunt virus (Lakatos et al. 2004),
the two agrobacterial cultures were mixed at equal concentration prior to infiltration.
4.2.3 Stable expression of SBA in S. tuberosum
Solanum tuberosum mini-tubers were generated as described previously (Bourque et al.
1987). Overnight cultures of Agrobacterium with pBI-rSBA were used to transform tubers as
previously described (Ma et al. 2005). Regenerating plantlets were transferred to magenta boxes
containing MS media supplemented with 50µg/L kanamycin. The presence of the transgene in
transgenic plants was confirmed by PCR, and PCR-positive plants were then selected to produce
mini tubers for protein expression analysis.
For mini tuber induction, a stem section (1 cm) with one resting auxiliary bud and one
fully developed leaf was excised from a sterile magenta-grown transgenic plant. The leaf was
removed and the stem was transferred to tuber inducing medium as described above and placed
in darkness at 20°C. After 4 weeks, the formed tubers (3 mm in diameter) were harvested and
used for protein analysis.
4.2.4 Accumulation of rSBA in Nicotiana benthamiana and potato plants
Total soluble protein was extracted from infected N. benthamiana leaf tissue or potato
tuber and then quantified as described previously (Tremblay et al. 2008). Briefly, approximately
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100mg of plant material, either Solanum tuberosum tuber or Nicotiana benthamiana leaf, was
ground in 1.5mL tube with a plastic pestle and mixed with protein extraction buffer (200 mM
Tris pH8.0, 100 mM NaCl, 400 mM Sucrose, 1 mM phenyl-methylsulfonyl fluoride, 10 mM
EDTA, 14 mM ß-mercaptoethanol, 0.05% v/v Tween-20, 2 µg/ml leupeptin, 2 µg/ml aprotinin).
The mixture was incubated on ice for 30 minutes and clarified by centrifugation at 10,000xg for
10 minutes at 4oC. The supernatant was transferred to a new 1.5mL tube and used for all
subsequent assays. Protein samples, boiled or unboiled, were loaded on to a 12.5% (w/v) SDSPAGE gel and resolved. Gels were then either stained with Coomassie Blue to visualize protein
profile or transferred to PVDF membrane as described previously (Tremblay et al. 2008). The
blot was then blocked for 1 hour at room temperature with 5% w/v milk in TBS-T and washed 3
times 5 minutes with TBS-T. The blots were incubated overnight at 4oC in 1:2000 rabbit antiSBA (Cedarlane AL-1301-2) in 1/3 blocking buffer 2/3 wash buffer. The blots were washed 3
times for 10 minutes in wash buffer and incubated in 1:5000 goat anti-rabbit-HRP (G-7641,
Sigma) for 1 hour at room temperature. The blots were washed 3 times for 10 minutes in wash
buffer and then incubated with SuperSignal® West Pico Chemiluminescent Substrate (34080,
Pierce, Rockford, IL). Blots were exposed and then developed using a film processor.
4.2.5 Quantification of plant-derived rSBA
The amount of accumulated rSBA in Nicotiana benthamiana leaves or Solanum
tuberosum tubers was quantified by enzyme linked immunosorbent assay (ELISA). Briefly,
commercial native SBA standard (Sigma L-1395) and triplicate NtrSBA or StrSBA samples
were bound to 96 well plates by incubation in phosphate buffer overnight at 40C. The plates were
then washed with PBS-T and blocked with 3% (w/v) BSA in PBS-T for 1 hour at room
temperature. The plates were washed 3 times and then incubated overnight at 4oC in 1:2000
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rabbit anti-SBA in 1/2 blocking:1/2 wash buffer. The plates were washed 3 times and incubated
for 1 hour at room temperature with 1:5000 goat anti-rabbit-HRP in 1/2 blocking:1/2 wash buffer
and then rinsed 3 times. The plates were incubated with Substrate Reagent Pack (DY999, R&D
Systems) according to the manufacturer’s instructions. The color was developed for 20 minutes
and then stopped with 1 times volume 2M H2SO4. The plate was then read using a Thermomax
microplate reader (Molecular Devices, USA). Standard curves were calculated and used to
determine protein concentrations of the individual samples. Negative control was protein extract
prepared from wild-type plant tissue.
4.2.6 Purification of plant-derived rSBA
Purification of rSBA from Nicotiana benthamiana or potato tubers was carried out
according to the protocol for GE Healthcare HisTrap HP column (#17-5248-01) or using an Nacetylgalactosamine-agarose column. For purification with the N-acetylgalactosamine-agarose
column, agarose columns with pre-bound N-acetylgalactosamine (Sigma A2787-5mL) were
washed and equilibrated with 0.1M NaCl. The TSP containing rSBA was then applied to the
column and rinsed with excess 0.1M NaCl. Samples were taken throughout rinsing and total
protein in rinse was determined by spectrophotometry at A280. Once protein levels were
negligible, rSBA was eluted with 0.5M galactose/0.1M NaCl. The purified protein was
confirmed via Western blot and then desalted via dialysis against excess 0.5xPBS buffer.
4.2.7 Hemagglutination Assay
Hemagglutination assay was performed using 2% rabbit red blood cells (RBC) suspended
in saline buffer. Commercial native SBA standard and purified NtrSBA and StrSBA were used
for the assay. The proteins were diluted into saline at varying concentrations in order to
determine the effective unit for each sample, with one unit defined as the amount of SBA

82
required to induce agglutination (Lin et al. 2008). All agglutination assays were repeated in
triplicate. Fifty µl of 2% RBC were added to round bottom 96-well plates and then mixed with
50µl protein dilutions. The mixture was then allowed to settle for 1 hour and images were taken,
with agglutination visually scored as positive or negative for agglutination in the well.
4.2.8 Competitive sugar binding assay
Sugar binding assay was carried out as described above for hemagglutination, with the
following modifications. One unit of native SBA or NbrSBA or StrSBA was mixed with saline
containing 40µM or 400µM concentrations of one of the following sugars: Nacetylgalactosamine, N-acetylglucosamine, arabinose, lactose or raffinose. Fifty µl of the
mixture was then added to 50µl 2% RBC and incubated for one hour. The results were then
photographed and each well was visually scored as positive or negative for hemagglutination.
4.2.9 Deglycosylation of plant-derived rSBA
Deglycosylation of NbrSBA and StrSBA was carried out with PNGase F according to the
manufacturer’s protocol (Sigma P-9120-1SET). The samples were then loaded onto an SDSPAGE gel followed by Western blot analysis using anti-SBA antibody. N-linked glycan removal
was confirmed via a band shift on the Western blot. To confirm the presence of mannose-type
glycans on plant-derived rSBA, blots containing both PNGase F–treated and untreated samples
were incubated with 20 µg/mL of Concanavalin A (C-2010, Sigma) at room temperature for 1 h.
After several washes with 0.5% (v/v) Tween-20 in PBS (pH 7.5), the blot was incubated with
HRP-conjugated anti-ConA antibodies (HAL-1104-1, E.Y. Laboratories Inc) at 1000-fold
dilution for 1 h. After the same wash step, the blot was incubated with SuperSignal® West Pico
Chemiluminescent Substrate. The signals were then developed using a film processor.
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4.2.10 Digestion of rSBA in SGF and SIF
The analysis of in vitro digestion of NbrSBA was carried out using either simulated
gastric fluid (SGF) or simulated intestinal fluid (SIF). For SGF (0.2g NaCl, 0.32g pepsin, 700 µl
HCl, in 100mL H2O, final pH 2.5) and SIF (0.68g monobasic KH2PO4, 7.7mL 0.2N NaOH, 1.0g
pancreatin, in 100mL H2O, final pH ~6.8), purified protein was incubated in a 37oC water bath
with samples taken and mixed in neutralization buffer (1.7g Na2CO3 in 100mL H2O) at time 0,
15s, 30s, 1m, 5m, 15m and 30m. Samples were boiled for 10 min, separated on a 12.5% (w/v)
SDS-PAGE gel and subjected to Western blot analysis as described above. Control native SBA
and a non-glycoprotein, human GAD65 made in E. coli (Plantigen), were also tested.
4.3 Results
4.3.1 Isolation and cloning of cDNA encoding SBA
To obtain a cDNA clone encoding SBA, RNA was extracted from wild-type soybean
seeds that were approximately 1-5mm in size, converted into cDNA that was then used as a
template for the PCR cloning of the SBA coding sequence. The primers included the addition of
a 5’ NcoI and 3’ XbaI restriction sites to facilitate sub-cloning of the PCR products, as well as
the addition of the 6xhistidine tag to the C-terminus. The cloned SBA gene was confirmed by
sequence analysis. For the convenience of sub-cloning, the internal HindIII site within the native
SBA coding sequence was removed by converting a G to an A in 2nd codon position encoding
serine, resulting in no change of the amino acid. The complete SBA expression cassette was
released from the pRTL-rSBA via HindIII digestion and inserted into pBI101.1 to form pBIrSBA (Figure 4.1). The plasmid pBI-rSBA was then transferred into A. tumifaciens strain
LBA4404 for plant transformations.
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Figure 4.1: Construction of plasmid pBI-rSBA. Construction of pBI-rSBA was described in detail in Methods. The
SBA gene contains an engineered 6xhistidine tag at its 3’ end prior to the stop codon. rSBA is expressed under the
control of a CaMV 35S promoter, the 5’UTR from tobacco etch virus (TEV) and the 3’ terminator from nopaline
synthase (Nos). The expression cassette contains resistance to kanamycin (NptII).
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4.3.2 Transient production of rSBA in Nicotiana benthamiana
Six week old N. benthamiana plants were infiltrated with the A. tumefaciens clone
harboring pBI-rSBA or mixed with cultures of A. tumefaciens containing the p19 expression
cassette, a viral suppressor of post-transcriptional gene silencing that has proven effective in
increasing the yield of transiently expressed proteins (Lakatos et al. 2004) (Figure 4.2A). Leaf
samples were collected from three independent plants on different days post infiltration with
different concentrations of A. tumefaciens cultures, with an equal amount of p19 added for each
assay, to determine the peak of rSBA expression in the agroinfiltrated N. benthamiana plants.
The results of immunoblot analysis showed that the highest expression using the PTGS
suppressor p19 was reached at day 5, with an optimal density of Agrobacterium of 0.25 OD600
(Figure 4.2B,C). As calculated by ELISA, the accumulation level of rSBA at day 5 reached up to
4% of TSP (Figure 4.2D). Examination of unreduced samples on SDS-PAGE gels followed by
Western blotting showed the presence of two bands, one corresponding in size to the monomer
and the other equivalent to the size of the tetramer of SBA (Figure 4.3), suggesting that N.
benthamiana made rSBA was assembled into a tetrameric protein complex, essential for its
biological activity.
4.3.3 Production of rSBA in stable Solanum tuberosum
Stably transformed potato plants were also tested for the expression of rSBA. Thirteen individual
transgenic potato lines were generated following Agrobacterium-mediated transformation and
transferred to mini-tuber inducing medium to generate consistently sized tubers for further
analysis. Immunoblot analysis of rSBA expression in unboiled samples of tuber extract showed
two major bands of 32 kDa and just over 100 kDa (Figure 4.3), expected for the
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Figure 4.2: Western blot analysis of transient protein expression of rSBA in Nicotiana benthamiana. A) Western
blot showing the accumulation of NbrSBA with (+) and without (-) p19, which was used in all subsequent transient
assays. B) Accumulation of rSBA from 1 day after infiltration (DAI) to 9 DAI. + is native SBA. C) Accumulation of
rSBA at day 5 with different OD600 of Agrobacterium. + is native SBA, NB is Nicotiana benthamiana wild-type
TSP. D) ELISA data for accumulation at days 1-9 after infection at optimized concentration. Value expressed as
percent total soluble protein (TSP), with each bar representing the mean value of the three collected samples
repeated in triplicate from each day with standard error. All Western blots were loaded with approximately 30µg of
TSP per lane, 150ng native SBA control.
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Figure 4.3: Detection of tetrameric structure of rSBA. Unboiled samples from Nicotiana benthamiana (Nb) and
Solanum tuberosum (St) in were subjected to SDS-PAGE and Western blotting. Unboiled native SBA (+) sample
was used as a positive control. The large arrowhead points to the tetramer, with an expected size of ~120 kDa. The
solid arrow indicates the position of the monomer with expected size of 32 kDa. The amount of protein loaded per
lane was 1 µg for native SBA, ~ 30µg TSP from N. benthamiana and 150µg TSP from mini tubers.
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monomer and tetramer of SBA, respectively. Immunoblot analysis of boiled samples of tuber
extract showed only the small band of 32 kDa (data not shown). The level of StrSBA
accumulation in potato mini-tubers was variable among individual transgenic lines, ranging from
no detectable signal to 0.31% TSP (Figure 4.4).
4.3.4 Purification of plant-derived rSBA
SBA specifically binds to N-acetylgalactosamine, allowing for the purification of this
protein via an N-acetylgalactosamine-agarose column to a high degree of purity. The purification
through this column also serves as confirmation for authentic SBA production. Figure 3.4A
shows that sugar-specific purification of rSBA from Nicotiana benthamiana leaf extracts
resulted in efficient protein retention during purification and elution. In addition, the sugarpurified sample was of high-quality when examined on SDS-PAGE gel and Coomassie blue
staining (Figure 4.5B). Sugar-specific purification of rSBA from potato mini tubers also resulted
in high-quality, purified protein (data not shown). As a control, the isolation of Nicotiana
benthamiana-derived rSBA using a traditional HisTrap column was additionally performed
(Figure 3.5B).
4.3.5 Hemagglutinating activity of plant-derived rSBA
Soybean agglutinin is known to agglutinate human and animal red blood cells
(hemagglutination). rSBA was therefore assessed for its ability to agglutinate rabbit erythrocytes.
Purified NbrSBA was found to induce the agglutination (clumping) of rabbit erythrocytes within
1 hour of treatment (Figure 4.6A). Similar results were obtained with StrSBA (data not shown).
The minimum amount of native SBA required to induce agglutination in the assay was 2.5 µg,
while NbrSBA and StrSBA required approximately 2 and 3.5 µg, respectively. As agglutination
of erythrocytes by SBA is due to its ability to bind to specific sugar residues on the cell surface,
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Figure 4.4: Accumulation of rSBA in potato tubers. Accumulation levels of rSBA in independent Solanum
tuberosum transgenic lines were determined by ELISA. Value expressed as percent total soluble protein (TSP), with
each bar representing the mean value of each sample repeated in triplicate from each day with standard error.
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Figure 4.5: Purification of rSBA. A) Western blot showing the purification of NbrSBA using either His purification
(H) or N-acetylgalactosamine (S). + is native SBA, TSP is total soluble protein prepared from Nicotiana
benthamiana, FT is flow through, W is wash, Pur is purified. No signals were detected in FT-S. B) Coomassie
stained SDS-PAGE gel. Note the single band in Pur-S at 32 kDa, equivalent to the expected monomer size. Numbers
on the left of the blots represent the molecular mass (kDa) of the protein ladder.
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Figure 4.6: Hemagglutination/Sugar inhibition study. Rabbit red blood cells undergo agglutination when treated
with SBA, due to the presence of N-acetylgalactosamine on membrane bound proteins. A) Agglutination of rabbit
red blood cells (RBC) following treatment with native SBA control or Nicotiana benthamiana-derived rSBA,
resulting in clumping around the bottom of the well. UT, untreated RBC, as characterized by RBC settling to the
bottom of the well. B) N-acetylgalactosamine inhibition. Both native SBA and Nicotiana benthamiana-derived
rSBA are inhibited by N-acetylgalactosamine, allowing RBCs to pellet.
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it is therefore speculated that the agglutinating activity of SBA could be inhibited by addition of
specific sugars. Indeed, addition of N-acetylgalactosamine even at low concentrations was able
to prevent the agglutinating ability of NbrSBA, similarly to the native SBA control (Figure
4.6B). In contrast, the agglutinating ability of NbrSBA or native SBA was unaffected by high
concentrations of non-specific sugars (Table 4.1 and also see Figure 4.6b).
4.3.6 Plant-derived rSBA is glycosylated
Native SBA is a glycosylated protein with a single high-mannose glycan (Adar et al.
1997). The presence of glycosylation, while not required for assembly or function, is important
in maintaining the stability of SBA (Sinha and Surolia 2007). To determine the glycosylation
status of plant-derived rSBA, NbrSBA, StrSBA and SBA standard were digested with PNGase F
and analyzed by immunoblotting following separation by SDS-PAGE gels. Both SBA standard
and plant-derived rSBA had a decrease in molecular size of approximately 2 to 3 kDa, which is
an expected size for a single glycan (Figure 4.7A). To determine the type of glycans of plantderived rSBA, blots containing both PNGase F–treated and untreated NbrSBA, StrSBA and SBA
standard were incubated with ConA, which binds to N-linked mannose, and then with anti-ConA
antibody. Figure 4.7B showed that binding of ConA occurs only in the untreated samples, but no
binding to any of the PNGase F treated SBA proteins, suggesting that plant-derived rSBA
contains high-mannose type glycans, similar to native SBA.
4.3.7 Plant-derived rSBA is stable in simulated gastric and intestinal fluids
Plant-derived rSBA was further investigated in simulated gastric and simulated intestinal
fluid (SGF and SIF) to assess its stability in the digestive system. SGF (3.2 g/L pepsin, pH 2.5)
has been used to mimic the acidic stomach environment in animals, while SIF (10 g/L pancreatin
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Table 4.1: Sugar inhibition comparison of native SBA and rSBA

All sugars except N-acetlygalactosamine showed no effect on hemagglutination at
40 or 400 µm concentrations. + = hemagglutination, - = no hemagglutination
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Figure 4.7: Determination of glycosylation of plant-derived rSBA. A) Deglycosylation of NbrSBA and StrSBA
using PNGase F, which cleaves N-linked glycans. Native SBA (+), NbrSBA and StrSBA were treated by PNGase F,
and analysed by SDS-PAGE and Western blotting. Untreated samples were used as controls. + is native SBA. B)
Concanavalin A binding analysis. Plant-derived rSBA and native SBA, both untreated and treated with PNGase F,
were treated with ConA, which binds to N-linked mannose. ConA treated samples were analysed by SDS-PAGE
and Western blotting using mouse anti-ConA antibody. Binding to both untreated native and recombinant SBA, and
no binding to PNGase F treated samples, suggests the presence of high mannose-type glycans for both recombinant
and native SBA.
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pH 6.8) is used for proximal small bowel conditions. To this end, purified NbrSBA and native
SBA were used in simulated digestion experiments. The effect of SGF and SIF on the
degradation of NbrSBA, as evaluated by immunoblot analysis, is shown in Figure 4.8A,B. As
can be seen, NbrSBA remains relatively intact following digestion even for 30 minutes in either
solution. Native SBA showed similar resistance to SGF and SIF digestion (data not shown). To
ensure proper activity of the simulated fluids, E. coli-derived recombinant GAD65 (glutamic
acid decarboxylase) previously produced in our laboratory was tested as a control. The protein
lasts less than 1 minute in SGF and 5 minutes in SIF (Fig 4.8C,D).
4.4 Discussion
We have demonstrated the successful recombinant production of SBA through both
stable and transient expression in Solanum tuberosum and Nicotiana benthamiana, respectively.
SBA has served as an excellent system of choice to study the fundamentals of protein–
carbohydrate interaction (Loris et al. 1998; Sharon and Lis 1990). With a vast increase in
knowledge of SBA and other lectins, it has become apparent that SBA has many additional
applications, especially in medical and biotechnology-focused industrial areas such as the
utilization of SBA to selectively remove cancerous cells from whole blood without removing
normal T cells, to prevent graft-versus-host disease following transplant, or to enrich
hematopoietic stem cells (Bakalova and Ohba 2003; Yura et al. 2008; Kernan et al. 1987).
Moreover, recombinant SBA has the potential to serve as a carrier system for oral drug delivery
or to be used as an affinity tag for isolation of high-purity fusion proteins. To make these
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Figure 4.8: In vitro digestion of Nicotiana benthamiana-derived rSBA in SGF and SIF. A) NtrSBA is not degraded
in simulated gastric fluid (SGF), even after 30 minutes (m) incubation, demonstrating resistance to both low pH and
pepsin digestion. B) NtrSBA is stable during simulated intestinal fluid digestion (SIF). C) and D) E. coli made
hGAD65 is rapidly degraded in SGF and SIF, respectively. Each lane contains the starting equivalent of ~500 ng of
purified protein.
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applications feasible, however, a more affordable source of high-quality and quantity rSBA is
required. Previous recombinant production of SBA in tobacco was incidental, as it was simply
used as a marker for studying the promoter activity and as such, there were no assays performed
to confirm that the protein made retained authentic SBA activity (Lindstrom et al. 1990).
Similarly, recombinant production in both bacterial and mammalian cell culture was for the
purpose of elucidating the functional role of glycosylation and the produced recombinant SBA
was either lacking glycosylation (E. coli-derived) or had reduced agglutinating ability
(mammalian cell-derived) (Adar et al. 1997). Our goal was to develop a robust expression
system that can generate large quantities of low-cost authentic rSBA, which retains its binding
specificity to facilitate high-purity simplified protein isolation and maintains its stability in the
gastrointestinal tract (GI) needed for future use as a carrier molecule for oral drug delivery.
Authenticity of both NbrSBA and StrSBA was confirmed by several results. The
foremost is the binding and inhibition studies using rabbit red blood cells. SBA binds to different
surface proteins bearing N-acetylgalactosamine, and in the case of red blood cells, results in
hemagglutination (Gordon and Marquard 1974). Both of the plant-derived rSBAs were able to
induce hemagglutination of rabbit red blood cells, as did commercial native SBA standard. In
addition, a similar minimum amount of SBA, whether native or from N. benthamiana or S.
tuberosum, were able to induce agglutination. This suggests that, unlike monkey cell made SBA,
Nb/StrSBA is functionally equivalent to native SBA. Many lectins can induce hemagglutination,
however, so it is important to confirm the specificity of rSBA for its ligand. For example, the
Chinese black soybean variety is able to cause agglutination of rabbit red blood cells but is
inhibited by a different sugar, in that case melibiose (Lin et al. 2008). The inhibition of
hemagglutination through the addition of N-acetylgalactosamine but not other sugars confirms
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the rSBA retains the authentic binding profile of native SBA. In addition to this, the ability to
specifically purify high-quality rSBA via N-acetylgalactosamine bound to agarose further
confirms the authenticity of the recombinant protein, as there was no detectable level of rSBA in
either the flow-through or wash steps, only in the elution. The capture rate for this technique has
been reported at over 90% efficient, which is supported by the lack of rSBA signal in the flowthrough steps seen in figure 4.2b (Percin et al. 2009).
The ability to purify high quality rSBA also lends the potential to be used as an affinity
tag. Through genetic fusion with a gene of interest (GOI), it may be possible to first purify the
fusion protein on the sugar columns, followed by subsequent cleavage of the desired GOI via
specific endoproteolytic cleavage, such as with tobacco etch virus (TEV) protease (Tubb et al.
2009). A second possibility would be in combination with a linker intein, an intervening protein
sequence that can be induced to undergo n-terminal, c-terminal or both termini cleavage under
specific conditions (Evans et al. 2005). This could allow for cleavage of the GOI from rSBA
without any expensive proteases and result in high-purity protein. It should be mentioned that
due to the requirement of the tetrameric formation for proper SBA activity, the addition of a
fusion partner may affect the formation of a tetrameric SBA. However, several groups, including
our own, have previously demonstrated that other multimer forming proteins, such as the nontoxic B subunit of cholera toxin, retain their ability to form pentamers and bind to their target
ligand when fused with other proteins (Arakawa et al. 1998; Li et al. 2006a; Ruhlman et al. 2007;
Tremblay et al. 2008).
The production of rSBA was accomplished using both transient and stable transformation
of Nicotiana benthamiana and potato, respectively. Transient gene expression in plants offers a
number of advantages over stable genomic transformation in plants or other recombinant
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expression platforms. First and foremost is the rapidity with which new recombinant proteins can
be generated in sufficient quantities for in vitro analysis as well as in vivo studies at a speed not
possible with traditional bioreactors. This is best demonstrated in the generation of idiotpe
specific scFvs to treat non-Hodgkins lymphoma patients. Researchers were able to generate
patient-specific scFvs by first isolating the antibody fragments from the patient’s biopsy, cloning
and ligating it into a plant expression vector followed by transient expression in N. benthamiana,
generating recombinant plant-made scFvs in less than 16 weeks, something unachievable with
any other biological system (McCormick et al. 2008). Transient expression can also be used to
generate and validate new vaccines against future pandemics such as H1N1 or SARS, where
large quantities of vaccine are needed in a short-period of time in order to meet world-wide
demand. An additional benefit of transient expression in plants is the level of accumulation. In
our work, we achieved almost 4% accumulation of rSBA in less than a week. This is a 10-fold
increase over the accumulation seen in our stably transformed potato lines. Based on our data,
the transient system can generate an approximate yield of between 1.5-3g of rSBA per kg fresh
weight in one week, meaning that a greenhouse setting capable of producing 1000kg of tissue per
week could generate up to 3kg of purified rSBA every week.
The use of stable lines expressing rSBA can likewise prove advantageous. The
production of a stable expression platform provides long-term low-cost therapeutic proteins,
typically required where the therapeutic is commonly used in multiple individuals over a long
period of time, such as in the potential prevention of type 1 diabetes using glutamic acid
decarboxylase 65 (GAD65) (Ma et al. 2004). We were able to accumulate rSBA to over 0.3% of
TSP in transgenic potato tubers. A major benefit of tuber accumulation is the stability of
recombinant proteins during long periods of storage. In the production of monoclonal antibodies,
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for example, the recombinant antibodies were stable for over 6 months when stored in the dark at
room temperature, with little to no loss in either quantity or activity (De Wilde et al. 2002). This
makes potatoes an excellent system for recombinant protein production, as one of the major
disadvantages of field/greenhouse grown plants for recombinant production is losses in yield due
to protein degradation during transit and processing. An additional benefit for the use of tubers is
that they can be used to orally deliver the target protein with minimal processing, especially
given that potato tubers form a staple part of many cultures diets and can be processed for
consumption via freeze-drying that allows for ingestion without cooking and thus could help
minimize protein denaturation/loss during food preparation.
In vitro digestion of N. benthamiana-derived rSBA under simulated gastric and intestinal
conditions proved to be stable. There was no significant loss or degradation of the protein after
incubation of NbrSBA in SGF for 30 minutes as seen in figure 4.5A,C. These results suggest that
the plant-derived rSBA may hold great promise for using as a carrier system for oral delivery of
protein and peptide drugs. The oral route for drug delivery is the most preferred route and offers
considerable advantages: requiring neither sterile needles nor trained personnel, lower cost and
increased quality of life, increased access to large population, reduced side-effects often seen
with systemic delivery, and greater patient compliance and acceptability. However,
administration of therapeutic peptide or protein drugs by the oral route represents a major
challenge. Orally administered peptide or n protein drugs are readily degraded due to their
exposure to the harsh environment of the GI (low pH and various proteinases and peptidases).
Therefore, development of suitable delivery systems is crucial to the success of oral
administration of protein drugs. Plant-derived rSBA may provide an ideal vehicle for oral drug
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delivery. Moreover, SBA undergoes endocytosis through epithelial lining of the intestine, adding
to its potential as an adjuvant for therapeutic protein delivery (Benjamin et al. 1997).
A potential concern with the use of rSBA as a carrier system for targeted drug delivery is
its anti-nutritional property. Indeed, SBA is one of the predominant anti-nutritional factors
found in the raw soybean and accounts for approximately 50% of the growth inhibition in rats
fed unheated soybean (Liener 1996). However, its anti-nutritional activity is strictly dosedependent. A negative effect of SBA on growth and immune function in rats was observed only
when very high levels of this protein was given as diets (14 mg/per rat daily or equivalent to
0.2% of its body weight). In our previous work on oral tolerance induction in mice using plantderived autoantigenic protein, we showed that only microgram quantities (or <0.005 % of the
animal’s body weight) of the plant-derived antigen is required to induce a response (Ma et al.
2004). This suggests that when used as a carrier system, the minimum effective dose of rSBAantigen fusion protein required to be delivered is in the range of micrograms, not milligrams.
Delivery of microgram quantities of SBA to animals is safe (Tang et al. 2006; Buttle et al. 2001).
However, as with all therapeutics destined for human use, thorough studies would be required to
determine the overall bio-safety.
In conclusion, our work has demonstrated the feasibility of high accumulation, highpurity recombinant production of SBA. This is the first molecular characterization of rSBA in
plants. The availability of low-cost, high-quality rSBA may make many important applications
of this protein possible, especially in medical areas.
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5.1 Introduction
Plants have emerged as an increasing attractive expression system for production of
recombinant therapeutic proteins, including antibodies and vaccines. As bioreactors, plants
enable unlimited scalability, elimination of product contamination by mammalian pathogens, and
reduced production costs compared with microbial or animal cell-based systems (Boehm 2007;
Ma et al. 2008; Tremblay et al. 2010b). Plants can perform the complex post-translational
modification and processing required by many transgenic therapeutic proteins for biological
and/or immunological function. Furthermore, plant bioreactors have the short turn-around time
needed to obtain gram quantities of a recombinant protein in a matter of weeks when expressed
transiently. This is not only economically advantageous, but is also critical for rapid access to
life-saving biotechnology drugs and therapies. Additionally, edible transgenic plant tissue may
offer the possibility of allowing direct oral delivery of plant-derived therapeutic proteins and
peptides, eliminating the need for expensive downstream protein purification and processing.
However, compared to other expression systems, nuclear-transformed plants accumulate
relatively low levels of foreign proteins, thus necessitating the development of an efficient and
cost-effective system for high recovery of foreign proteins from plant tissues.
Soybean agglutinin (SBA), naturally occurring in soybean seeds, is a homotetrameric
lectin glycoprotein that binds to N-acetyl-D-galactosamine and is able to induce the agglutination
of cells with this glycan on their surface. SBA has shown great potential for medical
applications, including screening and treatment of breast cancer, isolation of fetal cells from
maternal blood for genetic screening, and the possibility as a carrier system for oral drug delivery
(de Mejia et al. 2003; Tremblay et al. 2010a). Furthermore, because of its unique and highly
specific binding affinity for N-acetyl-D-galactosamine, SBA could be potentially used to develop
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novel affinity purification methods for low-cost, simplified and high-purity isolation of highvalue foreign proteins when they were genetically fused to SBA. Previously it has been shown
that high purity tetrameric SBA could be obtained from soybean flour with more than 90% yield
following one-step purification on beads bearing N-acetyl-D-galactosamine (Percin et al. 2009).
However, to use SBA as an affinity tag for purification of proteins, it is often necessary to
produce the target protein as a SBA-tagged fusion protein. Consequently, a robust expression
system enabling to produce large amounts of recombinant SBA fusion proteins needs to be
established. Recently, we demonstrated the suitability and efficiency of transiently transformed
Nicotiana benthamiana for high-level production of recombinant SBA (rSBA) (Tremblay et al.
2010a). As expected, plant-derived rSBA forms stable tetramers, bind specifically to N-acetyl-Dgalactosamine, is rapidly isolated in high purity from total soluble protein and retains its ability
to induce agglutination. This demonstration opens the door to the use of plants as an economic
source of large quantities of recombinant SBA and potential SBA fusion proteins.
The goal of the present study is to determine whether plants are suitable for generating
large quantities of recombinant SBA fusion proteins, as one of our long-term goals is to develop
plant-derived SBA as a novel affinity tag for efficient and rapid purification of precious human
therapeutic proteins by genetic fusion. As a first step toward this goal, we have expressed a SBA
fusion protein containing a reporter protein, green fluorescent protein (GFP), in transiently
transformed N. benthamiana. GFP has been widely used to monitor transgene expression and
protein localization as it allows for non-invasive in vivo monitoring in the absence of any added
cofactor or substrate. In addition, a fusion SBA-GFP protein may have a variety of diagnostic
applications, including cancer diagnosis, reducing the costs associated with either
immunolabelling or chemical conjugation of SBA with a fluorophore for visualization. We
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demonstrate transient expression of SBA-GFP in N. benthamiana at levels higher than 2% of
total soluble protein (TSP). Furthermore, the plant-derived fusion protein assembles to form
tetramers essential for its stability, retains the capacity of SBA to induce cell agglutination and
the ability of GFP to fluoresce. Importantly, the fusion protein can be quickly isolated to high
purity via N-acetyl-D-galactosamine-column.
5.2 Materials and Methods
5.2.1 Generation of rSBA-GFP
GFP was cloned from pEarleyGate 103 (Earley et al. 2006) using the primers GFP F 5’
GTCGACATGGTAGATCTGACTAGTAAAGG

3’

and

GFP

R

5’

TCTAGATCAGCTAGCTTTGTATAGTTCATCCATGCC 3’, with restrictions SalI and XbaI,
respectively, underlined. The rSBA to be used for the fusion was cloned from pBI-rSBA
(Tremblay et al. 2010a) with the primers rSBA F 5’ AATCCATGGCTACTTC
AAAGTTGAAAACC 3’ and rSBA-Fus R 5’ CTCGAGGATGGCCTCATGCAACACAAAAC
3’, with restriction sites NcoI and XhoI, respectively, underlined. PCR amplification for both
products were as follows: 10 minutes at 94oC, 35 cycles of 1 minute at 94oC, 30 seconds at 60oC,
2 minutes at 72oC, followed by 10 minutes at 72oC. Both genes were cloned into pUC19 and
subsequently sequenced. The cloned genes were then ligated together and used to substitute the
GUS gene in pRTL-2, providing a 35S promoter and 5’ untranslated region from tobacco etch
virus (TEV) (Carrington and Freed 1990) and 3’ untranslated region from Agrobacterium
nopaline synthase gene (NOS). The entire cassette was then ligated into the pBI 101 binary
vector to generate pBI-rSBA-GFP. The newly generated plasmid was transferred to
Agrobacterium tumefaciens strain LBA4404 via tri-parental mating (Ma et al. 2005), confirmed
by PCR using the rSBA F and GFP R primers.
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5.2.2 Transient expression in N. benthamiana
Transient expression was performed as described previously (Tremblay et al. 2010a).
Agrobacterium carrying pBI-rSBA-GFP were mixed with Agrobacterium carrying p19 at a ratio
of 1:1 according to cell density readings at OD600, with concentrations of 0.1, 0.25 and 0.5 used
for infection. Samples were collected at day 3, 4 and 5 to determine optimal collection date and
concentration.
5.2.3 Accumulation of rSBA-GFP in N. benthamiana
Total soluble protein was extracted as previously described and quantified by the
Bradford method (Tremblay et al. 2010a). Western blotting was performed as previously
described, with either 5 or 20 µg of TSP loaded into each well. Following transfer onto PVDF
membrane, blots were blocked with 5% fat-free powdered milk (w/v) in TBS-T for 1 hour and
then incubated overnight at 4oC in primary antibody. Rabbit anti-SBA (Cedarlane AL-1301-2) at
1:2000 dilution was used for SBA detection and Mouse anti-GFP (Sigma G-1546) at 1:1000 was
used for GFP detection, both in 1/3 blocking buffer 2/3 TBS-T. Goat anti-rabbit HRP or goat
anti-mouse HRP secondary antibody was diluted 1:5000 in 1/3 blocking buffer 2/3 TBS-T and
incubated for 1 hour at room temperature. The blots were washed in TBS-T and then incubated
with SuperSignal West Pico Chemiluminescent Substrate (34080, Pierce, Rockford, IL, USA).
Blots were developed using film and a film processor. ELISA was performed as previously
described to determine the quantity and expression level of rSBA and rSBA-GFP prior to
purification.
5.2.4 GFP imaging
Stereoscopic images of leaves transiently expressing rSBA or rSBA-GFP were obtained
using a Zeiss SteReo Lumar V12 microscope (Carl Zeiss International, Germany) with attached
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fluorescence filters. All confocal imaging was achieved using a Leica TCS SP2 confocal laser
scanning microscope (Leica Microsystems, Germany). Plant material was either whole mounted
(Stereoscopic images) or leaf punches suspended on water between cover slips (Confocal
images). For confocal images of rSBA-GFP with red blood cells (RBC), agglutinated blood was
smeared between two coverslips.
5.2.5 rSBA-GFP purification
Purification of rSBA-GFP was carried out using an N-acetly-D-galactosamine-agarose
column as previously described (Tremblay et al. 2010a). Washes were monitored by
spectrophotometry at A280 and once the readings reached zero, samples were eluted with 0.5 M
galactose/0.1 M NaCl. Samples were confirmed by Western blot and dialyzed against excess 0.5
x PBS buffer to remove NaCl and galactose. Coomassie blue staining of SDS-PAGE gels was
used to determine the relative purity of the purified rSBA and rSBA-GFP samples, and a
Bradford method was performed to each dialyzed sample to determine the total amount of
protein present following purification. Purification efficiency was determined by dividing the
post-purification value by the pre-purification value.
5.2.6 Hemagglutination
Rabbit RBC agglutination was performed using a 2% RBC suspension in saline buffer.
rSBA was used as a control. Purified rSBA or rSBA-GFP was mixed with the RBC and allowed
to settle over the course of 1 hour at room temperature and then recorded. The agglutination
assays were performed in triplicate. For the induction of agglutination, 1 unit is defined as the
minimum amount of the protein required to induce agglutination (Lin et al. 2008). In this
experiment, 1 unit of rSBA was 3 µg, rSBA-GFP was 4.5 µg. Inhibition of agglutination was
performed by adding N-acetyl-D-galactosamine, N-acetyl-D-glucosamine, arabinose, lactose or
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raffinose to a concentration of 40 mM or 400 mM, allowing cells to settle for 1 hour at room
temperature and recording for induction of agglutination.
5.3 Results
5.3.1 Plasmid construction
We previously cloned SBA cDNA and used it as a template for the construction of a
SBA-GFP fusion gene (Tremblay et al. 2010a). To this end, a cloned GFP sequence was fused in
frame to the 3’ end of the SBA sequence and the resulting fusion construct was then confirmed
by sequence analysis. Expression of the fusion gene was placed under the control of a 35S
promoter (Figure 5.1a). The entire cassette was transferred into the pBI binary vector and
confirmed via PCR (data not shown). Agrobacterium containing the plasmid was used to
transiently express the recombinant SBA-GFP (rSBA-GFP) protein in Nicotiana benthamiana.
5.3.2 Transient expression of SBA-GFP
Western blotting was used to confirm the accumulation of rSBA-GFP fusion protein.
Transient expression was achieved with co-cultivation with p19, a potent inhibitor of plant RNA
silencing (Voinnet et al. 2003). Antibodies against either SBA or GFP identified a band
corresponding to the expected size of the fusion protein, ~65 kDa (Figure 5.1b,c). We used rSBA
alone or commercially available GFP as controls during Western blot analysis and identified the
expected band shift for the fusion protein, approximately 30 kDa in both cases. Optimization
experiments were carried out to determine the optimal initial concentration/date of collection for
rBSA-GFP. Maximum accumulation occurred on day 5 post infection with an Agrobacterium
cell density at OD600 of 0.5 (Figure 5.1c). On day 5, rSBA-GFP accumulated to just below 2.5%
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Figure 5.1: Construction and expression of rSBA-GFP. a) Expression cassette used for transient expression in N.
bethamiana, with kanamycin resistance (nptII) and rSBA-GFP fusion. b) Western blot of rSBA-GFP using anti-SBA
antibody. Control protein is tsp from rSBA-transformed plants. 20 µg of TSP loaded. c) Western blot of rSBA-GFP
from day 3 to day 5 post infection using anti-GFP antibody. Control is commercial GFP. 5 µg of TSP loaded. d)
Overexposed Western blot of rSBA-GFP using anti-GFP antibody. Samples were boiled for 10 minutes prior to
loading. 20 µg of TSP loaded.
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of total soluble protein. In addition, when using the anti-GFP antibody and a longer exposure, a
high molecular weight band was detected in samples boiled for 10 minutes that was larger than
the 200 kDa marker (Figure 5.1d). The predicted molecular mass for the rSBA-GFP tetramer is
~250 kDa.
5.3.3 rSBA-GFP retains the fluorescence characteristics of GFP
Fluorescence microscopy was used to confirm the correct folding of the GFP portion of
the fusion protein. Fluorescence was first detected using a stereoscope, which showed localized
regions of fluorescence that corresponded to the regions infiltrated with the rSBA-GFPcontaining Agrobacterium, while no signal was detected in leaves infected with rSBA alone
(Figure 5.2a,b). More detailed imaging was performed using scanning laser confocal
microscopy, again with rSBA alone as a control (Figure 5.2c). Two-channel detection was used
to separate the GFP signal from autofluorescence. The resulting images showed separate regions
of intensity, with punctate GFP signal detected in leaves expressing rSBA-GFP, but no GFP
channel signal in leaves expressing rSBA alone.
5.3.4 rSBA-GFP purification and recovery
Soybean agglutinin (SBA) specifically binds to N-acetyl-D-galactosamine, permitting one-step
affinity purification of this protein via an N-acetyl-D-galactosamine–agarose column to a high
degree of purity. Purification through ligand-based affinity chromatography also serves as
confirmation of authentic SBA production. The major goal of this work was to demonstrate if
SBA can be used as a tag for affinity purification of SBA-tagged fusion proteins expressed in
plants, and to determine if foreign proteins fused to SBA could have an adverse effect on the
structure and function of SBA. Using Coomassie brilliant blue stained SDS-PAGE gels, we
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Figure 5.2: In vivo detection of GFP signal. a) Fluorescence sterioscopic image of transient expression of rSBA in
N. bethamiana. b) Fluorescence sterioscopic image of transient expression of rSBA-GFP in N. bethamiana. c)
Fluorescence confocal images for rSBA and rSBA-GFP. Autofluorescence Channel = over 600nm, GFP channel =
between 505-535nm. Bar = 1cm (a,b), 10µm (c)
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detect a single band in the elution fraction from the column, with the size expected for rSBAGFP fusion protein (Figure 5.3). No other bands were detectable. Bradford quantification
following purification demonstrated the recovery of ~ 92% and 91% of rSBA and rSBA-GFP
proteins, respectively (Table 5.1). Our results suggest that plant-derived rSBA-GFP fusion
protein was properly assembled into a tetrameric form, which is required for ligand binding and
hence purification, and is readily purified with efficient recovery.
5.3.5 rSBA-GFP retains its ability to agglutinate red blood cells
Native SBA is able to induce the agglutination, or clumping, of red blood cells. We
performed a hemagglutination assay in order to confirm that rSBA-GFP retains the ability to
induce agglutination of rabbit erythrocytes following purification. As shown in Figure 5.4a,
rSBA-GFP was able to induce agglutination within 1 hour of treating the cells, similar to native
SBA. The induction of agglutination required 4 µg of rSBA-GFP, with native SBA requiring 3
µg. rSBA-GFP agglutination was inhibited in the presence of 40mM N-acetyl-D-galactosamine,
but was unaffected by a variety of other sugars (Table 5.2).
5.3.6 rSBA-GFP fluorescence is detected on agglutinated cells
We next examined whether rSBA-GFP agglutinated red blood cells produced
fluorescence signal due to the activity of GFP protein. Agglutinated blood cells were smeared
between 2 coverslips and then examined under the confocal microscope. Agglutinated bloods
cells can be seen as clumps of cells under white light (Figure 5.4b). When excited by 488 nm
light, fluorescence was detected from around cells agglutinated with rSBA-GFP, while those
cells agglutinated with rSBA alone showed no signal.
5.4 Discussion
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Figure 5.3: Coomassie Blue stained 12.5% (w/v) SDS-PAGE gel demonstrating purity of rSBA-GFP following
purification on N-acetyl-D-galactosamine agar column. Purified rSBA from N. benthamiana was used as a control.
The single band in each lane corresponds to the expected size for rSBA and rSBA-GFP, respectively. ~12ug and 9ug
of purified rSBA and rSBA-GFP loaded, respectively.
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Table 5.1: Purification efficiency
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Figure 5.4: rSBA-GFP interacts with rabbit red blood cells. a) Agglutination of RBCs by rSBA-GFP. 3 µg of rSBA
and 4.5 µg of rSBA-GFP induced agglutination. b) Fluorescence and white light confocal images of RBCs
agglutinated by either rSBA or rSBA-GFP.
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Table 5.2: Sugar inhibition comparison of rSBA and rSBA-GFP
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We have developed a novel strategy for purifying recombinant proteins expressed in
plants using SBA as an affinity tag. This was demonstrated through the design, production, and
characterization of a recombinant SBA-GFP fusion protein. We produced the SBA-GFP fusion
protein in N. benthamiana with accumulation near 2.5% of TSP. The fusion protein retained both
GFP and SBA activity, with detection of intra-cellular GFP in plants as well as on agglutinated
RBC. Importantly, rSBA-GFP was successfully purified to a high degree on a ligand specific
column and induced agglutination of RBC.
A number of assays confirmed the correct assembly and viability of both SBA and GFP.
The first step was the confirmation of assembly of the fusion protein, with Western blotting
using either anti-SBA or ant-GFP antibodies showing a band around the expected mass of the
fusion, 62 kDa. This confirmed that the fusion protein was expressed as a single recombinant
protein. In addition, with long exposure of the blots, a larger band over 200 kDa was detected
using the anti-GFP antibody, demonstrating the presence of the expected tetramer. While
previously we were only able to detect the tetramer form of rSBA without boiling the sample
(Tremblay et al. 2010a), we found the antibody against GFP is far more sensitive than against
SBA, allowing us to resolve tetramers even after extended boiling prior to loading. The ability to
purify the recombinant rSBA-GFP protein on the N-acetyl-D-galactosamine-agar column and the
ability to induce agglutination, both of which require SBA to assemble into a homotetramer,
confirms that SBA retains its biological activity in the presence of a C-terminal fusion with a
protein of interest, in this case GFP. GFP function was assayed through microscopic analysis
using both a stereomicroscope and scanning laser confocal microscope. In the case of the
stereoscopic analysis, regions immediately surrounding the sites of infection were obviously
fluorescing, while intervening regions as well as rSBA alone samples showed little detectable
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signal. The fluorescence confocal work demonstrates that the signal obtained is clearly GFP, as
there is no overlap with chloroplast autofluorescence and no signal was detected in the rSBA
controls. In addition, the signal detected was punctate, not dispersed, which may indicate that the
protein is being stored in protein bodies as opposed to throughout the ER or the cytosol. Given
that native SBA has been previously been shown to localize within protein bodies in Glycine
max, it is probable that recombinant SBA is also able to form protein bodies, given that it retains
the native SBA signal peptide, although further experiments would be required to confirm this
(Horisberger and Vonlanthen 1980).
Transient expression of the rSBA-GFP fusion protein was selected due to our previous
ability to achieve high level accumulation of rSBA alone (Tremblay et al. 2010a). Transient
expression offers a number of advantages for recombinant protein production, including a rapid
turn-around time from the conceptualization of the gene to be expressed to accumulation of
sufficient quantities of the gene of interest for further analysis and validation. This is especially
important with the design and implementation of new therapeutics to combat human pandemics
and disease. For instance, the ability to isolate and generate sufficient quantities of an idio-type
specific ScFvs for treatment of Non-Hogkin’s lymphoma was achievable in under 16 weeks
using transient expression in N. benthamiana, something unachievable with other bioreactor
platforms (McCormick et al. 2008). We did note a decrease in the percent of TSP for rSBA-GFP
compared to rSBA alone, although the accumulation still reached nearly 2.5% of TSP. There are
a variety of possible reasons for lower accumulation compared to rSBA alone. It is possible that
rSBA-GFP is less stable due to changes imparted by GFP on rSBA assembly. However, there
seems little evidence to suggest this possibility, as the recombinant rSBA-GFP performed
similarly to rSBA in purification, agglutination and was sufficiently stable to resist 10 minutes of
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boiling prior to loading on the SDS-PAGE gels, as demonstrated by the detection of the tetramer
during Western blotting. Another possibility is that the reduction in accumulation may be due to
the increase in recombinant protein size, nearly double that of rSBA alone. Additionally, we may
not have fully optimized the conditions for transient expression, as we performed minimal
optimization based on those conditions which proved effective for rSBA alone.
We were able to achieve a greater than 90% recovery of rSBA-GFP fusion protein from
total leaf extract in a simple, one-step process using N-acetyl-D-galactosamine-agarose columns
(Table 4.1). When examined for purity of the purified fusion protein by SDS-PAGE gels
followed by Coomassie blue staining, no other protein bands were detectable, suggesting very
high levels of purity (Figure 4.3). Compared to isolation of plant-derived rSBA alone, there were
no measurable differences found in terms of recovery rate and purity of the two recombinant
proteins isolated by the same agar column method (Table 4.1 and Figure 4.3). Our results
indicate that the binding affinity of SBA for specific carbohydrate residues is not affected when
it is expressed as a SBA fusion protein in plants. This demonstration is important, as it suggests
that SBA can be used not only as a fusion partner for the high-level expression of many
heterologous proteins in plants, but can also be used for their one-step purification with high
purity in a rapid and inexpensive way by the use of specific sugar ligands for SBA. It should be
mentioned that although the recovery efficiency of rSBA and rSBA-GFP is similar to that
previously described for native SBA extracted from soybean seeds (ie, over 90%) (Bajpai et al.
2005), the purified rSBA and rSBA-GFP from N. benthamiana leaf extract appears to have less
contaminating proteins SBA purified from soybeans. Our previous attempts to purify native SBA
from soybean seeds resulted in a product that still had minor contaminating protein bands
following identical purification conditions (data not shown). The most likely cause for this is the
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differences in the tissues used for extraction, with N. benthamiana leaves likely having less
proteins that are able to interact with the N-acetyl-D-galactosamine that is bound to the agar or
that are able to interact with SBA and thus be co-purified. Taken together, this supports the use
of transient expression in N. benthamiana as a vehicle for recombinant SBA-fusion production.
The generation of rSBA-GFP serves more than just providing an example of proof of
concept to demonstrate the feasibility and usefulness of SBA as a new affinity tag for simple,
rapid, and efficient purification of tagged proteins from plants. A fluorescent rSBA-GFP fusion
protein itself could have many potential applications, including detection of cell surface and
intracellular glycoconjugates with N-acetyl-D-galactosamine molecules by microscopy and flow
cytometry, localization of glycoproteins in gels, precipitation of glycoproteins in solution and
agglutination of specific cell types. Moreover, it should be mentioned that fluorescent rSBA-GFP
fusion protein may be particularly useful for the detection of cancer cells or monitoring tumour
progression. Benbassat et al (1987) reported the use of fluorescein-isothiocyanate-conjugated
SBA to assess the stage of lymphoid cell differentiation in human leukemic–lymphoma cell lines
and showed that a gradual increase in SBA labelling was correlated with stages of the cell
differentiation as reflected by increased fluorescence intensity. High affinity binding of
fluorescent SBA conjugates to other types of cancer cells has also been shown, including mouse
lymphoma T cells (Reese and Chow 1992) and human gastric carcinoma cells (Terashima et al.
1997). Fluorescent SBA conjugates are also reported to selectively bind to murine glial cells
(Luth et al. 1992) and the zona pellucida of the mammalian egg (Aviles et al. 1997). Currently, a
series of fluorescent SBA conjugates is commercially available but far too expensive for routine
use, partly because they were produced by using expensive chemical conjugation methods. Our
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demonstration that plants can express a functional recombinant SBA-GFP fusion protein at high
levels may provide a higher quality, more reliable, lower cost fluorescent SBA product.
In summary, we have developed a novel strategy for purification of recombinant proteins
expressed in plants, based on genetic fusion to SBA. We demonstrated the applicability of this
strategy by producing a SBA-GFP fusion protein at high levels in transiently transformed N.
benthamiana plants. The fusion protein was purified to a high degree in a one-step process on Nacetyl-D-galactosamine-agarose columns and retained both GFP and SBA activity. The detection
of GFP fluorescence on SBA-GFP agglutinated red blood cells further demonstrate that plantderived rSBA-GFP fusion protein itself may have many biological and medical applications such
as bio-sensing, detection of cancer cells, and recognition and isolation of targeted cells.
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CHAPTER 6

GENERAL DISCUSSION AND CONCLUSSIONS
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6.1 Plants as bioreactors
The worldwide increase in demand for recombinant proteins are ever increasing as new
applications are developed and therapeutics are approved for human use. Green plant bioreactors
may be able to help meet these rising demands but are still hamstringed by a number of major
hurdles. One such hurdle is the typically low levels of accumulation achievable in nucleartransformed plants. It has been estimated that stable protein accumulation will need to reach over
1% of TSP to compete commercially with traditional cell culture-based bioreactors (Kusnadi et
al. 1997). Chloroplast-based expression systems are currently the only green bioreactors able to
routinely surpass this 1% barrier, but they are unable to perform eukaryotic post-translational
modifications, such as glycosylation, drastically reducing the scope of potential applications
(Grevich and Daniell 2005; Cardi et al. 2010). The second major hurdle for plant bioreactors is
the cost associated with protein purification. Typically, purification accounts for nearly 80% of
the final cost of a recombinant protein product requiring high purity, such as the production of
protein therapeutics (Walsh 2002). The third major hurdle is in the production of short peptide
fragments that are needed in a variety of therapies, including the prevention of T1DM.
6.2 Generating small peptides as fusions with CTB
It is extremely difficult to produce short peptide sequences in plants, due to instability
and high turnover within the cells. One approach to combat this is through fusion with larger,
more stable molecules that can facilitate their generation and/or isolation. I chose to use CTB as
a fusion partner to help stabilize and express the p277 fragment of HSP60. CTB has been shown
to be an effective adjuvant to increase the efficacy of its fused partner, drastically reducing
delivery requirements (Arakawa et al. 1998). The fused protein was both stable and accumulated
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to just over 0.1% of TSP, while no expression was detected when p277 was expressed on its own
(data not shown).
Currently, phase III clinical trials for Diapep277 are underway, with results from the
phase II trials showing promise. Other antigen-based therapies, such as using GAD65 or insulin,
have not met with similar success. The generation of the CTB-p277 protein in transgenic plants
may offer a less expensive alternative to Diapep277, which is chemically synthesized. Further
pre-clinical feeding trials with NOD mice will help to validate CTB-p277 and its effectiveness in
the animal model of T1DM. This would include determining its relative dose requirements, both
in terms of quantity of plant material required as well as number of doses needed to induce
tolerance.
6.3 Increasing recombinant protein yield
This thesis has demonstrated a variety of approaches to address each of the above
hurdles. Through the disruption of starch in potato tubers by knocking down the expression of
AAT1, as shown in chapter 2, I was able to increase tuber biomass accumulation, the
concentration of soluble proteins in each tuber as well as increase the relative amount of a
recombinant monoclonal antibody in said tubers. While on its own AATP1 knockdown lines did
not achieve the theoretical 1% threshold, with the best line accumulating just over 0.5% of TSP,
it did achieve a 4-fold increase in yield per plant, potentially resulting in commercial viability.
There was a potential drawback in the newly generated potato lines, however. Tubers from the
riAATP1-10 line have lower proteinase inhibitors than wild-type, and indeed, the protein appears
less stable, with reduction of nearly 50% of TSP by 5 months post-harvest. This may reduce the
utility of the line for some applications, such as for oral delivery of minimally processed tubers
for the induction of oral tolerance in T1DM therapy. Further studies could focus on ways to
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induce the expression of the proteinase inhibitor complexes and determine its impact of the
tubers.
In addition, this work raised potential questions about the mechanisms involved in tuber
development. The riAATP1-10 tubers had an increase in leaf scar number, as well as increased
length to width ratios. Typically, tubers develop at the terminal end of a stolon and once the
bulking stage occurs, all growth, both in length and width, is confined to the area already
differentiated as a tuber. Hence, small tubers and large tubers typically have similar numbers of
leaf scars, with the spacing between them increasing with size. In riAATP1-10, however, the
largest tubers had significantly more leaf scars than either wild-type tubers (figure 2.3b) or
smaller riAATP1-10 tubers (data not shown). This suggests that elongation of riAATP1-10
tubers may occur along the length of the stolon instead of being confined to the already
differentiated portion. Further study into the impact of sink strength on delineating the axis of
growth in tubers could prove interesting.
6.4 SBA is an effective affinity tag
The second major hurdle limiting the utility of plant bioreactors is that of purification. In
order to surpass this hurdle, a novel affinity tag was developed and described in chapters 3 and 4.
The use of the plant lectin SBA as an affinity tag offers the opportunity for high-efficiency onestep purification of a bound protein of interest, with GFP used as a first-step proof-of-concept in
this thesis. Recombinant SBA was shown to retain native SBA features, even when genetically
fused with GFP. These included the formation of stable tetramers in vivo, the ability to purify
with high efficiency and purity using affinity chromatography with the ligand, N-acetyl-Dgalactosamine, bound to agar, as well as the ability to induce the agglutination of rabbit RBC.
Throughout the process, GFP retained its fluorescence ability, both in vivo during transient
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expression in N. bethamiana and in vitro following purification and induction of agglutination of
RBC. Follow-up experiments for this work should focus on expanding the range of proteins
fused with SBA, as well as the introduction of protease cleavage sites, such as the tobacco etch
virus protease recognition sequence, or the use of self-cleaving inteins (Carrington and
Dougherty 1987; Evans et al. 2005).
GFP was selected as the fusion partner for these experiments for more than just its ability
to be monitored at each step of the process. SBA has previously been shown to bind
differentially to cell surfaces, a feature that has been led to its use in screening healthy tissues
from those that are cancerous. Traditionally, this was achieved using either chemical conjugation
of a fluorescent molecule, such as Alexa Fluor-488, or performing immunohistochemistry, where
antibodies against SBA that are conjugated with a detectable signalling molecule, such as
horseradish peroxidase. Both of these techniques are expensive, especially chemical conjugation
with Alexa Fluor-488. The ability to generate relatively low-cost SBA-GFP fusion proteins may
offer a less expensive alternative for distinguishing between cell types, although further research
is needed to determine if the signal strength of GFP is sufficient for rapid identification.
6.5 Perspective
Plants really are several potential bioreactors all wrapped in one package. If what you
need is large quantities of proteins that do not require post-translation modifications, chloroplasts
can potentially yield over 50% of soluble protein (Lentz et al. 2010). If you encounter a new
epidemic and need custom vaccines in a short period of time, transient expression can yield
between 2 to 10% of soluble protein and can produce significant quantities of protein in under 2
months (McCormick et al. 1999). Plants also have the potential to deliver large quantities of lowcost glycoproteins over a long-period of time through stable nuclear expression.
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There are, however, hurdles beyond simply making and purifying proteins from plants
that must be addressed. Primarily, these are regulatory in nature, with grave concerns being
raised about the safety of the food supply and possible risks of contaminating crops destined for
consumption with transgenics. While a variety of options exist to limit this risk, such as
transgene containment through male sterile lines and crop isolation within greenhouse spaces,
they cannot eliminate the risk completely. This could limit the use of crop species, such as
potato, in the production of recombinant proteins, despite the advantages that these crops may
provide. A more realistic alternative is through recombinant protein production in non-food
staple crops, such as tobacco and its relatives, in combination with greenhouse bio-containment.
The direction that plant green bioreactors will take will depend on the prevailing public
sentiment. Dissemination of high quality, high impact results to the public sphere in a way that
makes the data accessible, along with open discussions to address the fears and concerns over
transgenics, may help to increase public awareness and opinion. An open dialogue with the
public and government can ensure that regulations are implemented that protect the public
interest while at the same time allowing the public to reap the benefits of low-cost recombinant
proteins to help in their everyday lives, such as therapeutics and in the production of biofuels. As
long as the sun keeps shining, green bioreactors should have a bright future.
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